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MOLECULAR INSIGHTS INTO PAF1-MEDIATED PANCREATIC
HOMEOSTASIS, STEMNESS, AND CANCER PROGRESSION
Saswati Karmakar, Ph.D.
University of Nebraska Medical Center, 2020
Advisor: Surinder K. Batra, Ph.D.
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease that has one of the lowest 5year survival rates among cancers, at just 9%. This grim prognosis is primarily due to the
extensive metastatic spread of tumor cells beyond the pancreas at diagnosis and the inability
of current therapeutic modalities to treat this aggressive disease effectively. Given that the
cancer cells in pancreatic tumors are heterogeneous, the major culprit for cancer initiation,
progression, and metastasis remains elusive. Recent studies provide evidence for the
existence of highly tumorigenic and drug-resistant cells that are capable of tumor initiation,
known as the cancer stem cells (CSCs). The resistance to standard chemotherapy,
metastatic potential, and resultant aggressiveness of PDAC have been attributed to an
inadequate understanding of how these pancreatic CSCs are maintained within the tumor
and a lack of effective strategies to target them. In my doctoral research, I have attempted to
address these knowledge gaps by studying a protein, RNA polymerase II-associated factor
1 (PAF1) that is more than 30-fold overexpressed in the aggressive, poorly differentiated
tumors compared to well-differentiated tumors. Our previous work demonstrated that PAF1
or pancreatic differentiation 2 (PD2), is a novel CSC marker that mediates drug resistance
and metastasis in PDAC. PAF1 is a core component of human PAF1 complex (PAF1C),
which along with 4 other components (LEO1, CTR9, CDC73, and SKI8) recruits RNA
polymerase II for transcriptional elongation. Paf1 also maintains the self-renewal of mouse
embryonic stem cells and ovarian CSCs via its interaction with OCT3/4, a major regulator of
pluripotency. However, the mechanistic role of PAF1 in CSC maintenance and CSCmediated PDAC pathogenesis is poorly understood.
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In this dissertation, my first goal was to delineate the underlying mechanism of PAF1mediated CSC maintenance. I established that PAF1 downregulation decreased
tumorigenesis and metastasis in xenograft mouse models using multiple PDAC cell lines.
Moreover, PAF1 was overexpressed in isolated CSCs and was essential for regulating the
phenotypic features of CSCs such as in vitro tumor sphere formation and colony formation.
Interestingly, the other PAF1C subunits, LEO1, CTR9, and CDC73, appeared dispensable
for the maintenance of stem cell state, as their downregulation affected neither the
expression of CSC markers nor the formation of tumor spheres. Through IP-mass
spectrometry, I identified PHD finger protein 5a (PHF5A) and DEAD-box RNA helicase 3
(DDX3) as unique interacting partners for PAF1 in CSCs. Using a global approach via
chromatin immunoprecipitation sequencing (ChIP-Seq) with PAF1 and PHF5A-pulldown, I
found that promoters of several stemness regulators were occupied by PAF1 and PHF5A in
CSCs. Nanog was amongst the top genes whose promoters were jointly occupied by PAF1
and PHF5A in CSCs. Next, I investigated the effect of RK-33, a specific small-molecule
inhibitor of DDX3 helicase activity on pancreatic CSCs. Treatment of CSCs with RK-33 led
to a significant downregulation of CSC markers (β-CATENIN, CD44v6, SOX9, and NANOG),
inhibition of tumor sphere formation, and impairment of PAF1 binding to Nanog promoter.
Additionally, treatment with RK-33 resulted in apoptosis of CSCs, while minimal cell death
was seen in normal human fibroblasts. Overall, the data indicated that PAF1 functions as the
master regulator for stem cell maintenance by regulating the transcription of several stem
cell-related genes via a PAF1C-independent mechanism.
My second goal was to explore the functional impact of Paf1 depletion on the
pancreatic homeostasis using a CRISPR/Cas9-based conditional knockout mouse model.
The deletion of Paf1 from the mouse pancreas caused a significant decrease in pancreas
weight in young mice (up to 5-months old), without affecting the body weight. Histologically,
8

Paf1 loss caused an extensive loss of acinar parenchyma with associated inflammation and
appearance of ‘naked ducts’ embedded in fat. However, the ‘naked-duct like’ phenotype was
restored in older mice (7-, 9-, and 12-months old). RNA-seq analyses of the pancreas from
homozygous Paf1-deleted and floxed mice revealed pathways prevalent in system
development and acinar cell survival. Based on candidate players identified via RNA-seq and
other histochemical analyses, I showed that Paf1 plays a role in acinar lineage differentiation
and acinar maintenance. Next, to understand the role of Paf1 in PDAC progression, I
generated the KPCP (KrasG12D; Trp53R172H/+; Pdx1-Cre; Paf1fl/fl) PDAC mouse model. The
loss of Paf1 in the context of endogenous expression of KrasG12D and Trp53R172H/+ significantly
accelerated disease progression and decreased overall survival as compared to KPC mice
that have Kras and p53 mutations. Cell lines derived from KPCP mice showed a significantly
higher expression of mesenchymal markers (Vimentin and Snail) compared to KPC cell lines.
Altogether, I demonstrated a previously unknown role for Paf1 in acinar lineage differentiation
and provided molecular insights into Paf1-mediated cancer progression. In conclusion,
studies in this dissertation delineated the mechanistic role of PAF1 in CSC maintenance and
provided a means for selective targeting of pancreatic CSCs, as well as, elucidated the in
vivo role of PAF1 in pancreatic homeostasis and PDAC pathogenesis.
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CHAPTER 1
Introduction

The material covered in this chapter is the subject of one published review article.
Karmakar S., Dey P., Vaz AP., Bhaumik SR, Ponnusamy M.P., Batra S.K. PD2/PAF1 at the
crossroads of the cancer network. Cancer Research 2018; 78 (2):313-319.
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Synopsis
PD2 (Pancreatic Differentiation 2)/PAF1 (RNA Polymerase II-Associated Factor 1) is the core
subunit of the human PAF1 complex (PAF1C) that regulates the promoter-proximal pausing
of RNA polymerase II as well as transcription elongation and mRNA processing, and
coordinates events in mRNA stability and quality control. As an integral part of its transcription
regulatory function, PD2/PAF1 plays a role in post-translational histone covalent
modifications as well as regulates expression of critical genes of the cell cycle machinery.
PD2/PAF1 alone, and as a part of PAF1C, provides distinct roles in the maintenance of selfrenewal of embryonic stem cells and cancer stem cells, and in lineage differentiation. Thus,
PD2/PAF1 malfunction or its altered abundance is likely to affect normal cellular functions
leading to disease states. Indeed, PD2/PAF1 is found to be up-regulated in poorly
differentiated pancreatic cancer cells and has the capacity for neoplastic transformation when
ectopically expressed in mouse fibroblast cells. Likewise, PD2/PAF1 is up-regulated in
pancreatic and ovarian cancer stem cells. Here, we concisely describe multifaceted roles of
PD2/PAF1 associated with oncogenic transformation, and implicate PD2/PAF1 as an
attractive target for therapeutic development to combat malignancy.
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Introduction
The human PAF1(RNA polymerase II-Associated Factor 1) complex (PAF1C), an assembly
of five proteins (PAF1, CDC73, CTR9, LEO1, and SKI8 [1]), is highly conserved across
different species [1-3]. Similar to its yeast counterpart, PAF1C has a specific role in
transcriptional elongation, mRNA maturation and processing, histone covalent modifications,
and telomere silencing via its interaction with a variety of factors [2, 4, 5]. The majority of
interactions of PAF1C with its binding partners are primarily mediated through its PAF1 (also
known as pancreatic differentiation 2 or PD2) subunit. Therefore, PD2/PAF1 has evolved as
an integral part of the RNA polymerase II (Pol II)-associated molecular network and has been
shown to be a key player in important cellular processes including oncogenic transformation,
cell cycle, chromatin organization, stem cell self-renewal, and pluripotency [1, 6-10]. Of
interest, ectopic expression of PD2/PAF1 in NIH3T3 cells leads to increased cellular
proliferation and to aggravated tumorigenicity [9], which has underlined its role as a critical
tumor promoter when up-regulated. Indeed, PD2/PAF1 is up-regulated in poorly
differentiated pancreatic cancer (PC) cells [9], and an enhanced abundance of PD2/PAF1
induces pancreatic tumorigenesis and enhanced metastasis [11]. PD2/PAF1 has also been
implicated in development of other malignancies via its interaction and/or regulation of other
proteins. For instance, PD2/PAF1 is predicted to be a prognostic marker for early stage nonsmall cell lung cancer (NSCLC) as it is aberrantly elevated in early-stage NSCLC tumor
samples and promotes NSCLC tumorigenesis via c-MYC transcriptional activation [12].
Similarly, PAF1C interacts with CxxC-RD2 region of mixed lineage leukemia (MLL), a region
that is always retained in MLL-rearranged oncoproteins and this interaction is indispensable
for MLL-rearranged oncoproteins-mediated leukemogenesis [13]. In addition, PD2/PAF1 is
found to be upregulated in pancreatic and ovarian cancer stem cells (CSCs) [7, 14]. Here,

24

we discuss the varied functions of PD2/PAF1 with its involvement in oncogenesis, thus
placing PD2/PAF1 at the crossroads of the tumor network.
Historical perspective on PD2/PAF1 with function in transcription
PD2/PAF1 was originally identified as one of the genes having a 30-fold overexpression in
Panc1, a poorly differentiated PC cell line, compared to HPAF/CD11, a well-differentiated PC
cell line [9]. Mapping of the genomic location for PD2/PAF1 revealed that it is present in the
19q13.2 amplicon locus, which harbors the potent oncogene AKT2 [9], suggesting a
concerted function between PD2/PAF1 and AKT2 in stabilization of the locus. Domain
architecture of PD2/PAF1 (Figure 1) indicates possible interactions with RNA, concurrent
with its function as a key molecular member of the cellular transcription network and mRNA
stability [1].
As a member of PAF1C, PD2/PAF1 is involved in transcription elongation via direct
interactions with Pol II, Facilitates chromatin transcription (FACT), Positive Transcription
Elongation Factor (P-TEFb) and other factors [15-17] (Figure 1). The roles of PD2/PAF1 in
transcription have been reviewed elsewhere [15, 18]. We discuss here the less explored
function of PAF1C as the regulator of promoter-proximal pause release of Pol II, a
phenomenon essential for effective transcription elongation in metazoans. Pausing of Pol II
at 20-60 nucleotides downstream of the transcription start site, known as Pol II promoterproximal pausing, is mediated primarily via binding of DRB sensitivity-inducing factor (DSIF)
and negative elongation factor (NELF) to Pol II. Pause release is thought to require
phosphorylation of DSIF, NELF (and its subsequent dissociation), and C–terminal domain
(CTD) serine 2 (S 2) of the largest subunit of Pol II. (Figure 2). Chen et al. have recently
shown that loss of PD2/PAF1 in colorectal carcinoma HCT116 cells results in increased Pol
II occupancy within 9,333 gene bodies [19]. They further demonstrated that the Super
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Elongation Complex (SEC) is rapidly recruited to Pol II upon PD2/PAF1 loss [19].
However, Yu et al. propose that PD2/PAF1 may function as a positive or negative regulator
of Pol II promoter proximal pausing based on the physiological states and genetic
backgrounds of cells [17]. For instance, PD2/PAF1 knockdown in human acute lymphoblastic
leukemia CCRF-CEM cells caused a decrease in Pol II pausing in a majority of genes,
implying that PD2/PAF1 is a negative regulator of Pol II pausing release [17]. In contrast to
the results obtained in CCRF-CEM cells, knockdown of PD2/PAF1 in acute myeloid leukemia
THP1 cells led to increased promoter-proximal pausing of Pol II [17]. They also demonstrated
that PAF1C is responsible for recruitment of CDK12-Cyclin K, which has been suggested as
the predominant Pol II CTD Ser2 kinase. The role of PD2/Paf1 as the positive regulator of
promoter-proximal paused Pol II release is further supported in yeast [16], wherein the Nterminal domain of an mRNA capping enzyme Cet1 recruits FACT, which in turn targets
PAF1C to active genes for release of promoter proximally paused Pol II. In another study,
MYC-PAF1C interaction was reported to inhibit transition to the elongating form of Pol II as
proteasomal degradation of MYC promotes transcription elongation [20]. Thus, there is
ample literature suggesting that PD2/PAF1 plays specific roles in the regulation of Pol II
promoter-proximal pause release. Such functions of PD2/PAF1 underline its importance in
gene regulation in the pluripotency network. In the years following its discovery, PD2/PAF1
gained attention as a key oncogenic protein, overexpressed in various cancers such as
pancreatic cancer, ovarian cancer, non-small cell lung cancer, and endocrine tumors [1, 7,
9, 12, 21]. Our study demonstrating transformation of fibroblast cells on targeted
overexpression of PD2/PAF1 further emphasized its neoplastic action and encouraged
elucidation of its specific roles in tumor pathogenesis (Figure 3). Such outcomes could be
mediated via multiple pathways (e.g., cell cycle, histone covalent modifications, chromatin
remodeling, MAPK or mitogen activated protein kinase, estrogen signaling and others), as
described below.
26

PD2/PAF1 in regulation of cell cycle
As mentioned above, PD2/PAF1 is located in chromosome 19 concurrently with the Akt2
gene, which is an isoform of the serine-threonine protein kinase B family with a wellestablished role in regulating cell cycle [1, 22]. Thus, PD2/PAF1 is likely to be involved in
regulation of the cell cycle. Indeed, PD2/PAF1 has been found to control cell cycle genes
coherent with its temporally as well as spatially oscillatory expression patterns during cell
cycle progression, similar to the expression profile for cyclins. PD2/PAF1 specifically
regulates a subclass of genes (cyclins A1, A2, D1, E1, B1, and cyclin dependent kinase
CDK1) directly implicated in cell cycle progression during G1/S, S/G2, and G2/M (Figure 3A)
[8]. Expression of PD2/PAF1 also delays DNA replication but favors G2/M transition, in part
through microtubule assembly and mitotic spindle formation [8]. One of the hallmarks of
tumorigenesis is uncontrolled cell proliferation due to loss of cell cycle regulation. Thus,
upregulated PD2/PAF1 in pancreatic and other cancers might be involved in promoting cell
propagation during oncogenesis owing to its cell cycle regulatory function.
PD2/PAF1 in regulation of histone covalent modifications and chromatin remodeling
PAF1C facilitates the process of transcription elongation through recruitment of several
factors that perform post-translational histone covalent modifications [4, 6, 23-25] .
PD2/PAF1 as a part of the PAF1C has been found to regulate ubiquitylation of histone H2B
through interaction with RNF20/RNF40, which facilitates further downstream histone
covalent modifications including H3K4 and H3K79 methylation [24-26]. The PD2/PAF1
subunit of both yeast and human PAF1C has been shown to be involved in histone H3K4
and H3K79 methylation [6, 18, 24, 25, 27]. Furthermore, PD2/PAF1 regulates the
dimethylation and trimethylation of H3K4 through interaction with histone methyltransferase
[6]. Our study further demonstrates that interaction between PD2/PAF1 and CHD1 regulates
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nuclear import of CHD1, an ATPase-dependent chromatin remodeling protein, and their
interaction is responsible for nucleosomal structure rearrangement, which can lead to
subsequent changes in gene expression (Figure 3B) [6, 28]. Another independent study has
shown that PAF1C associates with the MLL complex, via contact with the PD2/PAF1 subunit
at the HOX gene locus to control leukemogenesis [13].
PD2/PAF1 as an effector of MAPK and estrogen signaling pathways
PAF1C is also found to act as a critical mediator in key signaling pathways related to
oncogenesis. For example, a recent study by Kim et al. shows that yeast Mpk1, a MAPK
activated in response to cellular stress, regulates transcription elongation in conjunction with
PAF1C via its interaction with PD2/Paf1 subunit through a conserved D motif [29]. Of interest,
complementation studies performed with human PD2/PAF1 and ERK5 (human homologue
of yeast Mpk1) demonstrate that this function is conserved in mammals as well [29]. Human
ERK5 is known to be a MAPK family member, one that plays a critical role in EGF (epidermal
growth factor)-induced cell proliferation [30]. Further, ERK5 transcriptional activity and
signaling has been correlated to tumorigenesis of breast and prostate [31, 32]. Another study
by Wu et al. highlights a novel role of human PAF1C as a ‘reader’ of the histone H3R17me2a
mark (Figure 3B) [33]. PAF1C is recruited to this specific histone modification mark by
CARM1 (coactivator-associated arginine methyltransferase 1) to regulate downstream
transcription of ERα (estrogen receptor α)-target genes such as pS2 that is found to be
overexpressed in breast cancer [33]. Interestingly, the recruitment of PAF1C to methylated
histones is achieved through strong binding via PD2/PAF1 subunit. Therefore, the role of
PD2/PAF1 as the chief interacting subunit of PAF1C in key signaling events associated with
oncogenesis reemphasizes its importance in cancer pathogenesis.
PD2/PAF1 in organogenesis, and maintenance of stem cells and cancer stem cells
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PAF1C is also implicated in the development of different species, from zebrafish to higher
eukaryotes [34-36]. It has been shown to regulate cardiac specification and heart
morphogenesis in zebrafish [34, 35]. Even in mammals, components of PAF1C such as
PD2/PAF1 and LEO1 appear to have roles in particular lineage specification [10, 36].
Silencing PD2/Paf1 in embryoid bodies has been shown to impair endodermal differentiation
[10]. Similarly, knockdown of LEO1 as well as PHD-finger protein 5a (Phf5a) blocks myogenic
differentiation [36]. Further, role of Phf5a in regulating myogenic differentiation appears to be
dependent on PAF1C, as it stabilizes PAF1C on chromatin promoting myogenic programs.
Indeed, loss of Phf5a led to a significant reduction in LEO1 occupancy at myogenic genes
[36]. These studies implicate the roles of PAF1C (or its components, PD2/PAF1 and LEO1)
in regulating the genes involved in pluripotency and organismal development.
Using a genome-wide screen for key pluripotency genes such as Oct3/4, Ding et al.
found PAF1C to be an important candidate for regulating stemness [37]. Our study also
shows that PD2/Paf1 heterozygous knockout in mouse embryonic stem cells affects
maintenance of embryonic stem cells by downregulating Oct3/4, Sox2, and Nanog, critical
“gate-keeper” and self-renewal genes highly expressed in early embryonic development for
maintenance of pluripotency [10]. Further, PD2/Paf1 plays an independent role in regulating
self-renewal of mouse embryonic stem cells by interacting with Oct3/4 (Figure 3C) [10]. From
this perspective, the role of PD2/PAF1 in self-renewal is described below in light of its action
on CSCs’ maintenance. CSCs are considered a small population of stem/progenitor or
“cancer-initiating” cells residing within the tumor cell mass, drug resistant and capable of
repopulating it. Of interest, PD2/PAF1 is elevated in pancreatic CSCs compared to nonCSCs, along with other well-known CSC markers such as OCT3/4 and SHH [14]. More
importantly, loss of PD2/PAF1 expression led to reduced viability of CSCs with a decrease
in expression of multi-drug resistant genes and stem-cell markers [14]. Further, we recently
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reported that PD2/PAF1 interacts with OCT3/4 to maintain self-renewal of ovarian CSCs,
independently of PAF1C [7]. Therefore, PD2/PAF1 emerges as a key molecule in
maintenance of CSCs that contribute to tumor recurrence.
PD2/PAF1 in Acinar-to-Ductal Metaplasia (ADM) in pancreatic cancer
Based on the multi-faceted roles of PD2/PAF1 in PC cells, all intrinsically linked to its
transcription regulatory function, we propose that PD2/PAF1 plays a unique role during PC
pathogenesis. Indeed, PD2/Paf1 is involved in ADM, an early event contributing to PC
initiation [38]. We illustrate that PD2/Paf1 is absent in normal pancreatic ducts, but
specifically present in metaplastic ducts [38]. Of interest, cerulein-induced acinar-to-ductal
trans-differentiation in mouse model is accompanied by loss of PD2/Paf1 expression, along
with reduced acinar markers. Further, downregulation of PD2/Paf1 in pancreatic acinar cells
leads to decrease in acinar marker genes, with a simultaneous increase in ductal marker
expression, indicating a possible role of PD2/Paf1 in maintaining acinar cell lineage (Figure
3D). These findings are particularly intriguing in the light of earlier findings that demonstrated
the role of several pancreas specific transcription factors, including Mist1, Sox9, and Hnf1a
in ADM and PC development [38]. Future studies will be directed towards delineating the
exact mechanisms underlying the role of PD2/PAF1 in PC initiation.

Conclusion and Perspectives
As described above, PD2/PAF1 is a key molecular mastermind of major cellular pathways,
and its deregulation is associated with cellular transformation. As a recent paradigm in the
field of understanding tumor development, disease relapse, and chemoresistance, studies
have begun to focus on the emerging role of CSCs as potent initiator cells, and PD2/PAF1
is upregulated in CSCs. The embryonic stem cell transcriptional and chromatin modifying
networks are critical for self-renewal maintenance, and PD2/PAF1 is involved in both
30

processes, hence determining the differentiation fate of embryonic stem cells. Moreover,
CHD1, an ATP-dependent chromatin remodeling protein regulated by PD2/PAF1, is known
to be important for maintaining open chromatin structure and maintenance of stem cells selfrenewal and pluripotency [6]. Additionally, Wdr5, a component of the histone
methyltransferase complex, MLL1 that interacts with PD2/PAF1, is also known to mediate
self-renewal and reprogramming via the stem cells core transcriptional network [39]. Thus,
PD2/PAF1 is involved in many important cellular events, particularly those related to selfrenewal and pluripotency, and malfunction or misregulation of PD2/PAF1 is associated with
cellular transformation. Our findings underlining the importance of PD2/PAF1 in maintenance
of self-renewal of CSCs [7] implicate PD2/PAF1 as an attractive target for combating CSCmediated tumor progression and recurrence. The recent findings demonstrating the “unholy
nexus” of PD2/PAF1 and the MAPK pathway further highlights its oncogenic potential.
Therefore, PD2/PAF1 lies at the heart of many important cellular events, and hence, serves
different functions as a part of the larger network. PD2/PAF1 appears to be the “master
regulator” that handles these multiple cellular chores simultaneously. Thus, PD2/PAF1
deregulation would tip the balance from normal cellular homeostasis towards oncogenic
transformation. Naturally, an in-depth understanding of the detailed functions and modes of
actions of PD2/PAF1 is crucial in the context of developing cancer therapeutics.

31

Figure Legends
Figure 1: PAF1 complex (PAF1C) and its interacting partners. Human PAF1C consists
of 5 components: PAF1 or PD2 (Pancreatic differentiation 2), CDC73, SKI8, LEO1, and
CTR9. The domain organization of PD2/PAF1 consists of three Myc type helix-loop-helix, a
leucine zipper (LZ), an RNA recognition motif (RRM), Ser/Asp-rich region, a Glu-rich domain
and a nuclear localization signal (NLS). PAF1C interacts with a variety of factors involved in
histone covalent modifications, transcription and mRNA 3’ end processing. These include
histone chaperone FACT (Facilitates chromatin transcription), RNF20/RNF40 (that catalyzes
histone H2B monoubiquitination), methyltransferases such as mixed lineage leukemia 1
(MLL1) that methylates histone H3 at K4, RNA Pol II, CDK12/ Cyclin K complex, positive
transcription elongation factor b (P-TEFb), elongation factors such as TFIIS (Dst1/SII) and
DRB sensitivity-inducing factor (DSIF), human cleavage and poly (A) factors that include
cleavage and polyadenylation specificity factor (CPSF) and cleavage stimulation factor
(CstF).
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Figure 2: PD2/PAF1 as the regulator of RNA Pol II promoter-proximal pausing. Although
PD2/PAF1 is found to regulate promoter-proximal Pol II pause release, two opposing models
have been proposed. In one model, positive transcription elongation factor b (P-TEFb) as a
part of the super elongation complex (SEC) is responsible for serine 5 (S5) phosphorylation
of the CTD (C-terminal domain) of the largest subunit of Pol II, DSIF and negative elongation
factor (NELF), leading to subsequent dissociation of NELF. Further, P-TEFb recruits PAF1C
to promoter proximal regions, which in turn recruits the CDK12/Cyclin K complex for serine
2 (S2) phosphorylation of the Pol II CTD, resulting in productive Pol II elongation (left panel)
[17]. In another model, the loss of PAF1C is essential for recruitment of SEC, which mediates
Pol II CTD S2 phosphorylation (right panel) [19]. Phosphorylation of DSIF and NELF (and
subsequent dissociation) is also required for effective Pol II pause release along with S2
phosphorylation of the Pol II CTD.
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Figure 3: PD2/PAF1 as a master regulator of key cellular processes. PD2/PAF1 and
PAF1C have several distinct functions in key cellular processes. A. PD2/PAF1 controls cell
cycle progression by specifically regulating a subclass of genes (cyclins A1, A2, D1, E1, B1,
and cyclin dependent kinase, CDK1) implicated in cell cycle progression during G1/S, S/G2,
and G2/M. B. PD2/PAF1 performs histone covalent modifications and chromatin remodeling
via interaction with the histone methyltransferase MLL1 and regulates the expression as well
as nuclear import of CHD1 (an ATPase dependent chromatin remodeling protein that
specifically binds to methylated-K4 of histone H3). PAF1C is a ‘reader’ of the histone
H3R17me2a mark (di-methylated arginine of histone H3) and is recruited to this specific
histone modification mark by CARM1 (coactivator-associated arginine methyltransferase 1)
to regulate downstream transcription of ERα (estrogen receptor α) target genes such as pS2.
ERE, estrogen responsive element. C. PD2/PAF1 interacts with Oct3/4 in mouse embryonic
stem cells (ESCs) and ovarian cancer stem cells (CSCs), and thereby promotes self-renewal
possibly by regulating self-renewal genes. D. PD2/Paf1 is expressed in acinar cells of normal
pancreas. However, in the case of progressive inflammation driven by cerulein treatment in
the background of Kras mutation, PD2/Paf1 is expressed in amylase and CK19 doublepositive metaplastic ducts that represent intermediate structures in the process of acinar to
ductal metaplasia (ADM). PD2/Paf1 expression is lost and regained during acinar transdifferentiation in PC initiation and it mediates regulation of lineage-specific markers. PanIN,
pancreatic intraepithelial neoplasia; and PDAC, pancreatic ductal adenocarcinoma.
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CHAPTER 2

Dissertation General Hypothesis and
Objectives
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1. Background and rationale
Pancreatic ductal adenocarcinoma (PDAC) is the third-leading cause of cancer-related
deaths in the United States and is projected to be the second-most lethal malignancy by
2030 [1, 2]. Asymptomatic nature, early metastasis, therapy resistance, and poor
understanding of underlying mechanisms of tumor heterogeneity and disease
pathogenesis are the primary contributors for the high lethality of PC [3-5]. Accumulating
evidence suggests that cancer stem cells (CSCs) are critical determinants of drug
resistance, tumor heterogeneity, disease aggressiveness, and metastasis of most
cancers, including PDAC [6-9]. Conventional chemotherapy is not directed towards CSCs
due to poor understanding of the molecular characteristics of CSC maintenance. A high
priority for future research is the molecular characterization of the CSC population to
improve survival for PDAC patients.
PAF1, a core component of RNA polymerase II-associated factor 1 complex (PAF1C),
functions in RNA polymerase II elongation and other transcription-coupled processes.
PAF1C is an assembly of five proteins: PAF1, CDC73, CTR9, LEO1, and SKI8 [10, 11].
Historically, transcription-related roles of PAF1C, including recruitment of 3’ endprocessing factors, H2B monoubiquitination, and H3K4 di- and tri-methylation, have been
investigated [10, 12-15]. However, while screening for markers of differentiation, our lab
found that PAF1 was more than 30 fold overexpressed in Panc1, a poorly differentiated
PDAC cell line compared to HPAF/CD11, a well-differentiated cell line [11]. Further, Paf1
was shown to be important for self-renewal of mouse embryonic stem cells by its
interaction with pluripotency master-regulator Oct3/4 [16]. Using a genome-wide screen
for key pluripotency genes such as Oct3/4, Ding et al. found PAF1C to be an important
candidate for regulating stemness [17]. Another study reported PAF1 to be a novel
pancreatic CSC marker and demonstrated its role in mediating drug resistance [18].
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Furthermore, PAF1 also maintains the self-renewal of ovarian CSCs [19]. Taken together,
all these studies establish that PAF1 is a multifunctional protein that plays important roles
in supporting self-renewal of stem cells and promoting the aggressiveness of CSCs.
Despite these pieces of evidence, it is still unclear how PAF1 supports CSCs
mechanistically. The first part of this thesis is primarily focused on deciphering the
mechanistic role of PAF1 in maintaining pancreatic CSCs.
Further, ectopic expression of PAF1 in NIH3T3 cells led to increased cellular proliferation
and aggravated tumorigenicity, which underlined its role as a critical tumor promoter when
up-regulated [11]. Moreover, an enhanced abundance of PAF1 led to increased
clonogenicity and migration in vitro, and tumor growth, and metastasis in vivo [20]. Based
on the multi-faceted roles of PAF1 in PC cells, all intrinsically linked to its transcription
regulatory function, we propose that PAF1 plays a unique role during PDAC pathogenesis.
Indeed, Paf1 has been shown to be involved in acinar to ductal metaplasia (ADM), an
early event contributing to PC initiation [21]. Dey et al showed that Paf1 is absent in normal
pancreatic ducts but specifically present in metaplastic ducts [21]. Of interest, ceruleininduced acinar-to-ductal trans-differentiation in the mouse model is accompanied by loss
of Paf1 expression, along with reduced acinar markers. Further, the downregulation of
Paf1 in pancreatic acinar cells leads to decrease in acinar marker genes, with a
simultaneous increase in ductal marker expression, indicating a possible role of Paf1 in
maintaining acinar cell lineage. Although genetic driver mutations for PDAC have been
defined, the initiating events that give rise to PDAC remain enigmatic [22-25]. Emerging
literature suggests the existence of a reserve stem-cell compartment in the pancreas that
is expanded upon an injury or insult leading to ADM and, ultimately, PDAC [22, 26-28].
The second part of this thesis is primarily focused on understanding the role of Paf1 in
PDAC initiation and progression using genetically engineered mouse models.
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2. Hypothesis
Based on the previous studies, we hypothesize that PAF1 promotes stemness and PDAC
oncogenesis, and pancreas-specific deletion of PAF1 has a profound effect on PDAC
progression.

3. Objectives
Aim 1: To investigate the mechanistic role of PAF1 in supporting pancreatic CSCs and to
identify a means for therapeutically targeting CSCs.
Aim 2: To explore the functional implications of Paf1 depletion on the pancreas
homeostasis in vivo through a CRISPR/Cas9-based conditional knockout mouse model
Aim 3: To understand the role of Paf1 in PDAC progression by use of KPCP (KrasG12D;
Trp53R172H/+; Pdx1-Cre; Paf1fl/fl) model.
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CHAPTER 3
Materials and Methods

Some of the material covered in this chapter was taken from one research article in
revision:

Karmakar S., Rauth S., Nallasamy P., Nimmakayala R.K., Leon F., Gupta R., Barkeer S.,
Venkata R.C., Raman V., Rachagani S., Ponnusamy M.P., Batra S.K. PAF1 promotes
stemness and pancreatic cancer oncogenesis independently of the canonical PAF1C via
PHF5A and DDX3. (In revision in Gastroenterology)
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1. Cell lines and cell culture
Human PC cell lines SW1990, CD18, Capan1, and the human pancreatic ductal cell line
HPDE were obtained from American type culture collection (Manassas, VA, USA).
SW1990, CD18, and Capan1 cells were cultured in Dulbecco’s modified Eagle’s medium
(4.5 mg/mL glucose) (HyClone Laboratories, Logan, UT, USA), supplemented with 10%
fetal bovine serum (FBS) (Sigma-Aldrich, St Louis, MO, USA)

and antibiotics (100

units/mL penicillin and 100 μg/mL streptomycin) (Sigma).
HPDE was cultured in human keratinocyte serum-free media supplemented with
epidermal growth factor 1-53 (EGF 1-53) and bovine pituitary extract (BPE) (Gibco).
An immortalized human pancreatic nestin-positive epithelial (hTERT-HPNE) cell line was
obtained as a generous gift from Dr. Ouellette at the University of Nebraska Medical
Center. It was cultured in Dulbecco’s modified Eagle’s medium (low glucose) with 25% M3
Base Media (Incell, San Antonio, TX), supplemented with 5% (vol/vol) fetal bovine serum,
10 ng/mL epidermal growth factor, and antibiotics (100 units/mL penicillin and 100 μg/mL
streptomycin).
Normal human fibroblast cell line 9-26 NP was derived from surgically obtained cancerassociated normal tissue. Briefly, the tissue was finely chopped and digested with
Liberase (Roche), and cultured in RPMI media (HyClone Laboratories, Logan, UT, USA)
supplemented with 1% HEPES, 1% sodium pyruvate, 1% L-glutamine, 1% sodium
bicarbonate, 1% non-essential amino acids, and 1% penicillin-streptomycin solution.
These cells were subjected to differential trypsinization up to 7 passages, immortalized
using hTERT, and then selected using puromycin to generate a stable fibroblast cell line.
Cells were incubated in a humidified incubator at 37 °C and supplied with 5% CO2. Cells
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were sub-cultured by trypsin-EDTA treatment and complete medium was changed every
other day.
Isolated CSCs or SP cells were cultured in stem cell medium: DMEM/F12 (Invitrogen,
Grand Island, NY) medium supplemented with 10% embryonic stem (ES)-specific FBS
(Invitrogen, Carlsbad, CA, USA), L-glutamine (GIBCO), 1000 U ml−1 leukemia inhibitory
factor (Sigma, St Louis, MO, USA), basic fibroblast growth factor (10 ng/mL)(Invitrogen)
and 0.5% penicillin-streptomycin solution.
2.Isolation of side population (SP) and non-side population (NSP) from cancer cell
lines
Side population (SP) cells or putative CSCs were isolated using flow sorting following
Hoechst 33342 (AnaSpec Inc., Fremont, CA, USA) staining as described previously[1].
Verapamil (Sigma), a calcium channel blocker that reverses the drug resistance
phenotype, was used as a control to gate the characteristic SP cells. The non-CSCs
exhibit a much higher intensity of Hoechst staining and fall outside the gate and are
therefore designated as the ‘non-side population’ (NSP) cells. Isolated SP and NSP
fractions from SW1990 and Capan1 were grown in DMEM with 10% FBS for a day to allow
the cells to acclimatise. The SP cells were then transferred to a stem cell-specific medium
and were cultured in gelatin-coated (Millipore Sigma, Burlington, MA, USA) culture dishes
as described previously[1]. SP cells were treated with 0.2 µM gemcitabine (IC20) for
enriching the CSC population.
3.Generation of CRISPR/Cas9 Paf1-conditional knockout mice with flanking LoxP
sites
For generating the Paf1 conditional knockout mouse model, we followed a novel approach
using the CRISPR/Cas9 system. The mouse Paf1 gene is located on chromosome 7 and
has 14 exons. For gene targeting, we chose exon number 4, which is 122 nucleotides
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long. In this design, the 3rd exon was spliced to the 5th exon such that there was a stop
codon falling in-frame immediately at the beginning of exon 5. This strategy resulted in
disruption of the protein coding sequence after exon 5. Translation of the first 3 exons
results in 57 amino acids (170 coding nucleotides), which is approximately only 10%
(57/535 amino acids) of the total protein size. We used a novel genome editing tool
developed in Dr. Gurumurthy’s lab at UNMC called Isi-CRISPR (ivTRT-ssDNA-insertionCRISPR: pronounced Easy-CRISPR) to insert loxP sites flanking exon 4. A long, singlestranded DNA (repair template) of about 600 bases containing left and right homology
arms of about 100 bases, one LoxP site each in intron 3 and 4 that flanked exon 4 was
synthesized using In vitro transcription and Reverse Transcription approach described in
Miura et al (Figure 1) [2]. The schematic of ssDNA repair template synthesis is shown.
Paf1 deletion from conditional knockout mouse model was validated using immunoblotting
analyses in mouse embryonic fibroblast (MEF) cell lines. Briefly, Paf1 homozygous males
and females were bred and embryos were collected from pregnant females at embryonic
day 13.5. The head portion of the embryos was used for isolating DNA for genotyping and
remaining torso was used for creation of MEF lines. The MEF lines derived from the
embryos were transduced with adenoviral Cre (GFP labelled) to induce removal of loxP
sites flanking exon 4 of Paf1 gene. The transduction efficiency was monitored via GFP
positivity of cells using fluorescence microscopy. Protein lysates were collected from
homozygous and heterozygous Paf1-deleted MEF cell lines as well as wild type cells and
analyzed for Paf1 expression using immunoblotting.
4.Generation of KPCP (KrasG12D; Trp53R172H/+; Pdx1-Cre; Paf1fl/fl) progression model
KPC (KrasG12D; Trp53R172H/+; Pdx1-Cre) and KPCP (KrasG12D; Trp53R172H/+; Pdx1-

Cre; Paf1fl/fl) were created by breeding of KrasG12D; Pdx1-Cre and LSLTrp53R172H/+ with
Paf1fl/fl. Further, intercrossing of their F1 progeny resulted in the generation of KPCP mice
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along with KPC control littermates. All of the animals were backcrossed several times to
C57BL/6 prior to breeding. For progression studies, KPC, KPCP, and age-matched
controls were euthanized at 3, 5, 10, 15 and 20 weeks of age (five animals/group/time
point). Survival studies were also conducted on KPC and KPCP mice (10-12
animals/group). All animal studies were performed in accordance with the U.S. Public
Health Service "Guidelines for the Care and Use of Laboratory Animals" under an
approved protocol by the University of Nebraska Medical Center Institutional Animal Care
and Use Committee (IACUC).
5.DNA isolation and genotyping
Mice at 15-21 days of age were tail clipped and DNA isolation was performed using
standard protocols (Maxwell 1f6 mouse tail DNA purification kit, Promega, Madison, WI,
USA). The genotyping of Kras, p53, Pdx1-Cre, Paf1fl/fl was performed by PCR using the
primer sequences mentioned in Table 1.
6.Human PC and normal pancreatic tissues
After approval of institutional review board at UNMC, formalin fixed paraffin-embedded
tissue specimens from pancreatic cancer patients who underwent Whipple surgery (n=30)
were retrieved. Additionally, we also obtained tissue arrays (US Biomax -T142) that were
representative of normal pancreatic tissues, chronic pancreatitis, PanIN lesions and PDAC
(i.e., well-differentiated, moderately differentiated, and poorly differentiated cancer).
7.Development of murine tumor cell lines and MEF cell lines
Mouse tumors or embryos were finely minced and then processed for cell line
development. Cell lines were derived using standard procedures using previously
described method [3]. Briefly, the tissue was digested using an enzymatic cocktail known
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as liberase (Roche) for 30 minutes at 370C. Following digestion, bigger tissue chunks were
removed through strainers and the flow through was collected. After centrifugation, the
cell pellet was washed twice and then plated. The media was changed after every 3-4
days and the fibroblasts were eliminated from tumor-derived epithelial cell lines using
differential trypsinization.
8.Organoid generation and culture
In brief, tumor organoids were established after tumor resection, mechanical and
enzymatic digestion of pancreatic tumor from KPC autochthonous mouse model with
0.012% (w/v) collagenase XI (Sigma) and 0.012% (w/v) dispase (GIBCO) in DMEM media
containing 1% FBS (GIBCO) and embedded in growth factor reduced (GFR) Matrigel
(BD)[4]. These organoids were maintained and cultured in complete DMEM/F12 medium
supplemented with HEPES (Invitrogen), Glutamax (Invitrogen), penicillin/streptomycin
(Invitrogen), B27 (Invitrogen), Primocin (1 mg/ml, InvivoGen), N-acetyl-L-cysteine (1 mM,
Sigma), mouse recombinant Wnt3a (100ng/ml, Millipore), human recombinant RSpondin1
(1μg/ml, Nuvelo), Noggin (0.1 mg/ml, Peprotech), epidermal growth factor (EGF, 50 ng/ml,
Peprotech), Gastrin (10 nM, Sigma), fibroblast growth factor 10 (FGF10, 100 ng/ml,
Preprotech), Nicotinamide (10 mM, Sigma), and A83- 01 (0.5 mM, Tocris). Human
organoids were derived from the pancreas tissue obtained from fresh tissue bank at
UNMC and cultured using the same protocol as followed with mouse organoids with
addition of Wnt3A (1X (50% V/V), Preprotech).
9.Orthotopic tumor implantation
SW1990, Capan1, and CD18 cell lines were engineered for inducible PAF1 knockdown
using a lentiviral system. For orthotopic studies, 0.5*106

engineered PDAC cells were

injected into the pancreas of 6-8-week-old nude mice (six to eight animals/group) using
conventional procedures. Doxycycline hyclate (Sigma-Aldrich) was administered to mice
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assigned to the PAF1 KD group via drinking water at a concentration of 2 mg/ml in 2%
sucrose solution. Control mice received 2% sucrose in drinking water. Euthanization of
experimental mice cohorts was performed 30-50 days after orthotopic transplantation.
Following euthanization, tumor weights and metastatic lesions were recorded.
10.Subcutaneous tumor implantation
Control and PAF1 KD cells (40,000) were suspended in 500 µl of PBS and mixed with
Matrigel (Fisher Scientific) in a 1:1 ratio. Cells (4,000) in 100 µl volume of PBS-matrigel
mix were injected subcutaneously into the right and left flanks of 5-week-old athymic nude
mice. Four mice were used per group and the appearance of tumors was checked by
palpitation two times per week. Animals were sacrificed soon after the tumor nodule
reached 0.8 cm diameter.
11. Immunohistochemistry (IHC)
IHC staining was performed on KPC and KPCCP mouse tissues. Briefly, after
deparaffinization with xylene and hydration with decreasing alcohol gradient, endogenous
peroxidase activity in the tissue sections was blocked by 3% H2O2 for an hour. Further,
antigen retrieval was done by heating these tissue slides in citrate buffer (10mM Sodium
Citrate, 0.05% Tween 20, pH 6.8) or Tris EDTA buffer (10mM Tris Base, 1mM EDTA
Solution, 0.05% Tween 20, pH 9.0) at 80°C for 20 minutes. After heating, the samples
were allowed to cool for 15–20 minutes in room temperature, followed by washing with
PBS (5 minutes × 2). Nonspecific binding was blocked by incubating the sections with
2.5% horse serum for 30 minutes (Impress reagent Kit, Vector, CA), which was followed
by their incubation with primary antibodies for 16 h in a humidified chamber at 4°C. The
tissues slides were subsequently subjected to three washes with PBS and then incubated
with secondary antibody (peroxidase-labeled Universal antimouse/antirabbit IgG) (Vector,
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Burlingame, CA) for 30 minutes. Sections were then washed with PBS followed by
treatment with diamino benzidine reagents (0.2 mg/ml) for 5 minutes. After washing with
distilled water, counterstaining was done using hematoxylin (Vector). After washing in tap
water, sections were dehydrated in graded alcohol and cleared with four xylene washes.
After overnight air drying, the slides were mounted in Permount permanent mounting
media (Fisher Scientific, Fair Lawn, NJ). All slides were observed under Nikon E400 light
microscope and representative photographs were taken. Expression of Paf1 and Vimentin
was analyzed by two pathologists at UNMC. An intensity (0 - no staining, 1 – weak
staining, 2 – moderate staining, and 3 – strong staining) and percentage of positive cells
(range 1– 4; 0–25% positive cells, equal score of 1, 26–50%, equal score 2, 51–75%,
equal score 3, and 76–100%, equal score 4) were recorded. A composite score obtained
by multiplying the two values was assigned and ranged from 0 to12.
12. Histology
Formalin-fixed mouse tumor tissues were paraffin embedded and sectioned. Following
sectioning, the tissues were subjected to H and E staining.
13.Depletion of PAF1 using CRISPR/Cas9 and inducible shRNA
PAF1 knockdown in SW1990 SP cells was performed using the CRISPR/Cas9 system.
Briefly, cells were transfected with a PAF1 guide RNA (5’-ACCTACCGCATCGACCCCAA
-3’) containing a CRISPR/Cas9 vector (pSpCas9 BB-2A-GFP PX458) (Genescript,
Piscataway, NJ, USA). GFP positive cells were isolated 72 h after transfection and the
pooled population was collected in a 12-well plate by flow sorting. Cells were allowed to
grow into colonies, which were then analyzed for expression of PAF1 by immunoblot
analysis.
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For inducible knockdown, TRIPZ inducible lentiviral human PAF1 shRNAs from
Dharmacon (Lafayette, CO, U.S.A.) were used. HEK293T cells were cultured and
transduced with sh23 and sh25 plasmids to generate viral supernatant according to
manufacturer’s instructions. Viral supernant was used to infect SW1990, CD18, Capan1,
SW1990 SP, and Capan1 SP cells, following which the cells were selected using
puromycin (4 µg/ml). Selected cells were subjected to doxycycline (Dox) treatment (2
µg/ml) for 72 h and then sorted for RFP expression. RFP+ cells were maintained under
two conditions, with and without Dox treatment, and were cultured under puromycin
selection pressure (4 µg/ml). Dox-induced shRNA-mediated knockdown of PAF1
expression was analyzed by immunoblot assay.
14.SiRNA-mediated transient knockdown
Transient knockdown of PAF1 was performed using PAF1 siRNA (Origene), which is a
pool of three target-specific 19-25 nt siRNAs. Capan1 SP cells were plated in a 6-well
plate at a concentration of 0.6 million/well. On the following day, the cells were serum
starved for 4 h, and then transfected with PAF1 siRNA or non-targeting control siRNA
(scramble siRNA) at a concentration of 80 pmol/well using TurboFect reagent
(ThermoFischer Scientific). Serum containing medium was added to the cells 4 h after
transfection. The medium was changed every 24 h and lysates were collected 72 h after
transfection. Knockdown of DDX3, PHF5A, LEO1, CDC73, and CTR9 was performed
using gene-specific siRNA (Origene) as described above.
15.ALDEFLUOR Assay
The cells expressing high levels of activity of the enzyme aldehyde dehydrogenase
(ALDH) were stained using ALDEFLUOR reagent (Stem Cell Technologies, Cambridge,
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MA, USA. Cat: 01700) using the manufacturer’s instructions. A specific inhibitor of ALDH,
diethylaminobenzaldehyde (DEAB), was used to control for background fluorescence.
16.Analysis of CD44+ CSCs using flow cytometry
Cells were trypsinized, counted, and resuspended to get one million cells/100 μl per tube.
Cells were incubated with human CD44-APC antibody (Miltenyi Biotec Inc. Auburn, CA,
USA.Cat:130-098-110) for 15 minutes at 4 °C, followed by two PBS washes and
resuspension in 500 μl media. Appropriate single and double color controls were included
and cells with a high expression of CD44+ (high CD44+) were gated using appropriate
controls.
17.Apoptosis Assay
SW1990 SP and 9-26 NP cells were treated with vehicle control DMSO or RK-33 (5M) for
48 h. Cell supernatant and adherent cells were collected, stained with annexin V and
propidium iodide (PI), and analysed by flow cytometry as described previously[5].
18.Immunoblot Assay
Cells were processed for protein isolation and Western Blotting using standard
procedures, as described previously [1]. Cells were typically grown for 48 hours in
complete media, unless mentioned otherwise, and total protein lysate was collected in
RIPA lysis buffer (50 mM Tris–Cl, pH 7.4; 150 mM NaCl; 1% Nonidet P-40; 0.25% Nadeoxycholate; 1 mM ethylenediaminetetraacetic acid; 1 mM phenylmethylsulfonyl fluoride;
1 µg/ml aprotinin and leupeptin; 1 mM Na3VO4; and 1 mM NaF) and passed through a 25gauge syringe several times. Total protein content was assayed with the Bio-Rad
DC Protein assay (Bio-Rad, Hercules, CA). Protein lysates (20 µg/ml) were resolved in
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (10%). Resolved proteins
were transferred to polyvinylidene difluoride membrane and blocked in nonfat milk (5%)
for 1 hour. The membrane was incubated in the appropriate primary antibody according
to the manufacturer's instructions overnight at 4 °C, followed by 4 × 10-minute washes in
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Tris-buffered saline Tween-20 (50 mM Tris–Cl, pH 7.4; 150 mM NaCl, and 0.05% Tween20). The membrane was incubated for 1 hour with the appropriate secondary antibody
conjugated with horseradish peroxide at the dilution of 1:2000 in PBS, followed by 4 × 10minute washes in Tris-buffered saline Tween-20. Enhanced chemiluminescence reagents
(Amersham Biosciences, Piscataway, NJ) were applied on the membrane as per the
manufacturer's instructions, and the blot was exposed to an ECL-sensitive film (Biomax
Films, Kodak, Rochester, NY).
The following primary antibodies were used: anti-PAF1, anti-LEO1, anti-CDC73, antiCTR9 (Bethyl Laboratories, Montgomery, TX, USA); anti-PHF5A (Proteintech, Rosemont,
Illinois, USA); anti-OCT3/4, anti-SOX-2, anti-CD24, anti-ESA (Santa Cruz Biotechnology,
Dallas, TX, USA); anti-CD44 (Cell signalling Technology, Danvers, MA, USA); anti-CD133
(Abnova, Walnut, CA, USA); anti–β-Catenin (Sigma); anti-DDX3, anti-Lgr5, and anti-SOX9 (Abcam, Cambridge, MA, USA). β-ACTIN was used as a loading control.
19.Immunofluorescence analysis
Cells were plated, fixed, and processed as described previously[1]. PDAC cells were
grown in a 12-well plate dish to 60% confluence on autoclaved coverslips for 48 hours.
Cells were fixed and permeabilized with ice-cold methanol (2-3 minutes). Blocking was
completed using 10% Bovine Serum Albumin (BSA) (Jackson Immunoresearch Labs, Inc.,
West Grove, PA, USA), which was followed by overnight incubation with Primary
antibodies at 4°C. Primary antibodies specific for mouse-PAF1 (1:100 in PBS), mouseOCT3/4 (1:100), rabbit-β-CATENIN (1:100), mouse-CD44 (1:250), and rabbit-ESA
(1:1500) were used. For human and mouse tissues, we followed the same procedure
mentioned previously[6], with deparaffinization and dehydration followed by antigen
retrieval and blocking. The cells/tissues were then washed with phosphate-buffered saline
(PBS) for 3 × 5 minutes and incubated in dark for 30 min with fluorophore-conjugated
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secondary antibodies (Jackson Immunoresearch Labs, Inc.) at room temperature.
Cells/tissues were washed again (5 × 5 minutes) in PBS and mounted on glass slides in
vectashield mounting medium that contained the nuclear staining dye DAPI (Vector
Laboratories, Burlingame, CA, USA). Confocal images were collected using Zeiss
LSM800 confocal microscope with a 63×/1.4 NA oil objective.
Quantification of fluorescent intensity: Multichannel snapshots were split into separate
channels in ImageJ. A region of interest was drawn around individual cells in one of the
two channels using the “freehand” tool. This region was then subjected to the measure
plugin, and intensity was calculated by multiplying area and mean intensity. The
measurement of intensity was made for 10 cells in a field and 5-6 images per condition.
The intensity values were represented relative to the control condition in arbitrary units
(A.U.).
20.Colony formation assay (clonogenic assay)
SW1990 SP PD2/PAF1 CRISPR KD cells and control SW1990 SP cells were trypsinized
and seeded at a density of 1000 cells/well in a 6-well plate in triplicates. The cells were
cultured in CSC-specific media, with media changed once in two days. After two weeks of
growth, the cells were fixed with 100% methanol and stained with crystal violet stain (0.1%,
w/v in 20 nm 4-morpholinepropanesulfonic acid; Sigma) before the colonies started to
merge. Total colony area was quantified using ImageJ.
21.Tumor sphere assay
Capan1 SP cells that were engineered to knockdown PAF1 using Dox-induced shRNA
were seeded in triplicates in a 96-well non-adherent plate (Corning Inc., Corning, New
York, USA) in CSC-specific media at a concentration of 100 cells/well in two sets. The
cells in suspension culture were observed under the microscope and fresh media was
added every alternate day without removing the existing media in the set designated as
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control, whereas the set designated as KD set received Dox at 2 µg/ml every alternate
day. In another experiment, treatment with RK-33 was initiated 24 h after cell seeding. The
number of tumor spheres (diameter >100 μm) for each well was evaluated after 10 days
of culture. Multiple images were taken per well for different fields of view. The diameter of
each tumor sphere was measured using Motic Images Plus 2.0 ML software; the plot
depicting the diameter of tumor sphere in PAF1 KD cells and control cells was plotted
using MedCalc software.
22.Cell motility assay
The motility assay was performed by using a chamber containing a monolayer-coated
polyethylene teraphthalate membrane (six-well insert, pore size of 8 μm; Becton
Dickinson, Franklin Lakes, NJ, USA). Both control and PAF1 knockdown (Dox treated)
SW1990 cells (1 × 106 cells per well) were seeded in six-well plates. After a 24 h incubation
period, the migrated cells that had reached the lower chamber were stained with a DiffQuick stain set and counted in different fields. The average number of migrated cells per
representative field was calculated.
23.Wound-healing assay
The wound-healing assay was performed as described previously[7]. Briefly, 4 × 106
control and PAF1 KD (2μM doxycycline treated) cells were seeded in 6-well plates. After
24 h, a scratch was made on the bottom of each well using a P200 pipette tip. Photographs
of the scratch were taken at 0 h and 24 h. The pictures were then analyzed to quantify the
change in size of the scratches as the cells migrated into the space; wound closure was
compared between control and PAF1 depleted cells.
24.Immunoprecipitation analysis
SW1990 SP, HPDE, and F9 cells were cultured in their respective culture conditions and
the lysates were collected in a CHAPS non-denaturing immunoprecipitation buffer (20 mM
Tris, pH 7.5, 200 mM NaCl, 1%). Immunoprecipitation was performed with PAF1 (ChIP62

grade, Abcam) and anti-Phf5a (Proteintech) antibodies using Dynabeads protein G
(Invitrogen). Following pre-clearing, 500 µg of lysates prepared at 1 mg/ml were incubated
with 3 µg of respective antibodies overnight in a rotor at 4 °C. The next day, dyna beads
(20 µl per reaction) were added to the antibody-lysate mix and incubated for rotation at 4
°C for 6 h. Thereafter, the unbound antibodies were washed with IP wash buffer (40 mM
HEPES pH 7.4, 500 mM NaCl, 2.5 mM MgCl2, 2 mM EGTA, and 1% Triton X-100), and
the immunoprecipitated proteins were eluted using a high pH ammonium buffer and were
concentrated using a speed Vac. The immunoprecipitates, or total cell lysates, were
transferred onto the PVDF membrane after being resolved on 10% SDS PAGE, and
thereafter were incubated overnight at 4 °C with primary antibodies (anti-PAF1, antiOCT3/4, anti-LEO1, anti-CTR9, and anti-CDC73).
25.RNA isolation and quantitative reverse-transcription Polymerase Chain Reaction
(qRT-PCR)
Total cellular RNA was extracted from cells using the RNAeasy kit (Qiagen, Valenica, CA,
U.S.A.) and processed for reverse transcription to generate cDNA as described
previously[8]. Specifically, 1 µg of the RNA was converted to cDNA, which was further
used for qRT-PCR quantification of PAF1 and CSC genes. cDNA products were assayed
by quantitative real‐time PCR using SYBR Green incorporation. The expression of all
genes was normalized to that of internal control β‐actin and expressed relative to the
indicated reference sample (average ± SEM of triplicate reactions).
26.Human transcription factors PCR array
Total RNA isolated from SW1990 SP and PAF1-depleted SP cells were reversetranscribed using RT2 SYBR qPCR master mix (330,401, Qiagen). Aliquots of 25 μl of the
mix of both samples were added in separate 96-well PCR array kits containing lyophilized
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gene-specific primer set (PAHS-075Z, Qiagen). Threshold cycles were used to calculate
fold change using the online web server of RT2 profiler PCR array data analysis[9].
27.Chromatin Immunoprecipitation (ChIP)-Sequencing
SW1990 SP cells were fixed with 0.4% formaldehyde and 1.5 mM EGS (ethylene glycol
bis(succinimidyl succinate)) (Thermo Scientific Fischer), washed, harvested, and
resuspended in 500 μl SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris‐HCl [pH 8.1],
1 mM PMSF, and 1 μg/ml aprotinin). Samples were sonicated and diluted in ChIP dilution
buffer (0.01% SDS, 1.1% Triton X‐100, 1.2 mM EDTA, 16.7 mM Tris‐HCl [pH 8.1], 167
mM NaCl, 1 mM PMSF, and 1 μg/ml aprotinin). For input control, 10% of sonicated
samples were separated. Immunoprecipitation was performed with ChIP‐grade PAF1
(Abcam) and Phf5a (Proteintech) antibody as previously described. Chromatin extracts
were pulled down with protein A+G beads. The samples were washed extensively with
wash buffers (low salt, high salt, LiCl, and Tris/EDTA buffers), eluted with SDS elution
buffer, and subjected to reverse cross-linking and proteinase digestion. IgG antibody was
used as a control for the ChIP assay.
ChIP-seq Analysis: The captured and purified DNA was prepared for high throughput
sequencing using the New England Biolabs NEBNext Ultra II DNA Library Prep Kit for
Illumina. The resulting indexed libraries were sequenced by the UNMC Sequencing Core
Facility using an Illumina NextSeq 500 Genome Analyzer. Initial raw sequence files were
processed based on the following steps. Adaptor sequences and low quality (Phred score
< 20) ends were trimmed from sequences using Trim Galore software package
(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Resulting fastq files
were aligned to the human genome (GRCh38/hg38) using the sequence aligner Bowtie2
(version

2.2.3)[10].

The

software

package

Picard

routine,

MarkDuplicates,

(http://broadinstitute.github.io/picard/) was used to remove sequence duplications. For
peak calling of ChIP enriched regions, the MACS2 peak caller software (version 2.1.1)[11]
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of each ChIP to corresponding input DNA sample was used to determine binding regions
based on a FDR adjusted p-value (q-value) <0.05. BigWig files were generated using the
deeptools

bamCoverage

routine

(https://deeptools.readthedocs.io/en/develop/).

Alignment of significant peaks to gene specific regions was accomplished using the
bedtools routine intersect (https://bedtools.readthedocs.io/en/latest/). Raw files were
submitted to GEO (accession number GSE144371).
28.RNA-Sequencing
SW1990 SP control and PAF1 CRISPR KD cells were lysed in RNA lysis buffer supplied
with the mirVana RNA isolation kit (Thermo Scientific Fischer, n = 2). Total RNA was
isolated in accordance with the manufacturer’s protocol. Whole transcriptome analysis
(RNA sequencing) was performed on PAF1 KD and control cells at the Sequencing Core
Facility at University of Nebraska Medical Center. RNA quality was checked with an
Agilent Bioanalyzer (Agilent Technologies, Inc.) and all RINs (RNA integrity numbers)
were 10. Library preparation was achieved using Illumina TruSeq RNA Sample
Preparation Kit according to the manufacturer’s protocol. Fifteen cycles of PCR
amplification were performed for each library, followed by examination of size distribution
using an Agilent Bioanalyzer (Agilent Technologies, Inc.) and a DNA 1000 chip. Each
sample used one out of twelve unique indices (Illumina). All libraries displayed a band
between 200–500 bp with a peak at approximately 290 bp. The Qubit 2.0 Fluorometer (Life
Technologies, Inc.) was used to quantitate the libraries. Loading was performed at a
concentration of 6 pM. Sequencing was done on HiSeq 2500 sequencer in rapid mode. It
was a single read, 50 cycle, sequencing run, and onboard clustering and V2 chemistry
was used. Raw files for RNA-seq were submitted to GEO (accession number
GSE144371).
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29.Mass Spectrometry
Sample prep summary: Protein fractions were excised from SDS-PAGE gel, destained,
reduced with tris-carboxyethylphosphine, alkylated with iodoacetamide, and digested
overnight with sequencing-grade trypsin (Promega). Tryptic peptides were eluted from the
gel and concentrated to 20 µl by vacuum centrifugation and analyzed using a highresolution mass spectrometry nano-LC-MS/MS Tribrid system, Orbitrap Fusion™
Lumos™ coupled with UltiMate 3000 HPLC system (Thermo Scientific). 500 ng of
peptides were run by the pre-column (Acclaim PepMap™ 100, 75µm × 2cm, nanoViper,
Thermo Scientific) and the analytical column (Acclaim PepMap™ RSCL, 75 µm × 50 cm,
nanoViper, Thermo Scientific). The samples were eluted using a 120-min linear gradient
of ACN (5-45%) in 0.1% FA.
Results summary: All MS/MS samples were analyzed using Mascot (Matrix Sciences,
London, UK, version 2.6.). Mascot was set up to search the SwissProt database (selected
for Homo sapiens, 2018_06, 20361 entries) assuming the digestion enzyme trypsin.
Parameters on MASCOT were set as follows: Enzyme: trypsin, Max missed cleavage: 1,
Peptide charge: 1+, 2+, and 3+, Peptide tolerance: ± 0.8 Da, Fixed modifications:
carbamidomethyl (C), Variable modifications: oxidation (M), MS/MS tolerance: ± 0.6 Da
with error tolerant search, Instrument: ESI-TRAP. MASCOT results for different gel cuts
of the same sample were combined and analyzed using Scaffold, which allows multiple
search results to be condensed into a single result file.
Scaffold (version 4.8.7, Proteome Software Inc., Portland, OR) was used to validate
MS/MS based peptide and protein identifications. Peptide identifications were accepted if
they could be established at greater than 95.0% probability by the Peptide Prophet
algorithm[12] with Scaffold delta-mass correction. Protein identifications were accepted if
they could be established at greater than 99.0% probability and contained at least 2
identified peptides. Protein probabilities were assigned by the Protein Prophet
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algorithm[13]. Proteins that contained similar peptides and could not be differentiated
based on MS/MS analysis alone were grouped to satisfy the principles of parsimony.
Proteins sharing significant peptide evidence were grouped into clusters.
30.In silico analysis of PAF1C subunits, PHF5A, and DDX3 in PC data sets
The GEPIA web server (http://gepia.cancer-pku.cn/) was used to analyze TCGA PC
expression data. Herein, expression data for PAF1, CTR9, LEO1, CDC73, SKI8, PHF5A,
and DDX3 were obtained. The data was downloaded using the web portal and
subsequently plotted[14]. The normalized PAAD gene expression data (FPKM-UQ) was
obtained from Genomic Data Commons (GDC) web portal (portal.gdc.cancer.gov).
Grouped boxplots of PAF1, other PAF1C subunits, DDX3, and PHF5A were made using
the ggplot2 package in R. The boxplots were grouped based on the ABSOLUTE purity
classifications, as provided by Raphael et al., 2017[15].
31. Reagents and Antibodies
Supplementary Table 1-5 in Chapter 4 outlines a thorough list of primers and antibodies
used in the study.
32.Statistical analysis
Student’s t-test was used to determine the statistical significance between control and
PAF1 knockdown group in all the experiments pertaining to this study. Statistical analysis
and generation of graphs were performed using GraphPad Prism and MedCalc software.
Alfa level of 0.05 was used for statistically significance unless otherwise indicated. Error
bars were given on the basis of calculated standard error values.
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Figure. 1: ivTRT-ssDNA-insertion-CRISPR method.
A. Schematic representation of ivTRT method to generate single stranded repair DNA to
develop CRISPR-Cas9 based Paf1 knockout animals. B. Diagram representing insertion
of single-stranded donor DNA containing two LoxP sites into Paf1 (PD2) exon 4.
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Figure 1
A. ivTRT method of generating ssDNA for Easy-CRISPR
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B. insertion of ssDNA donor DNA containing two loxP sites flanking
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Table 1: Primers for KrasG12D,Trp53R172H, and Pdx-1-Cre genotyping

Forward Primer
Reverse Primer
Forward Primer
Reverse Primer
Forward Primer
Reverse Primer

Kras
5’-CCTTTACAAGCGCACGCAGACTGTAGA-3'
5'-AGCTAGCCACCATGGCTTGAGTAAGTCTGCA-3'
P53
5'-CTTGGAGACATAGCCACACTG-3'
5'-AGCTAGCCACCATGGCTTGAGTAAGTCTGCA-3'
Pdx-1-Cre
5'-CTGGACTACATCTTGAGTTGC-3'
5'-GGTGTACGGTCAGTAAATTTG-3'
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CHAPTER 4
Molecular mechanisms governing PAF1mediated pancreatic cancer stemness

The material covered in this chapter is the subject of one research article in revision:
Karmakar S., Rauth S., Nallasamy P., Nimmakayala R.K., Leon F., Gupta R., Barkeer S.,
Venkata R.C., Raman V., Rachagani S., Ponnusamy M.P., Batra S.K. PAF1 promotes
stemness and pancreatic cancer oncogenesis independently of the canonical PAF1C via
PHF5A and DDX3. (In revision in Gastroenterology)
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Synopsis
Background and aims: Molecular governance of pancreatic cancer stem cells (CSCs) is
poorly understood, resulting in ineffective therapeutic interventions for pancreatic cancer
(PC). PAF1, a core component of RNA polymerase II-associated factor 1 complex
(PAF1C), functions in RNA polymerase II elongation and other transcription-coupled
processes. Additionally, PAF1 is essential for maintenance of pluripotency of stem cells
and is a novel CSC marker. However, the mechanistic underpinnings of PAF1-mediated
CSC maintenance remain elusive. Here, we sought to elucidate a novel mechanism for
PAF1 in promoting PC pathogenesis and its role in CSC maintenance.
Methods: PC cells engineered for inducible knockdown (KD) of PAF1 were orthotopically
implanted in the pancreas of athymic nude mice. Tumor growth was monitored via IVIS
imaging and the extent of metastases was determined at the endpoint. CSCs were
isolated from PC cells by flow sorting and characterized by in vitro tumor sphere formation,
in vivo tumorigenicity assays, and expression of CSC markers. PAF1 was silenced in
isolated CSCs using the CRISPR/Cas 9 system followed by expression analysis of CSC
markers. PAF1-regulated genes were identified via RNA sequencing (RNA-Seq) and PCR
array analyses. The PAF1 sub-complex in CSCs was identified using immunoprecipitation
(IP) - mass spectrometry (MS). ChIP (chromatin immunoprecipitation) sequencing was
performed in CSCs to confirm binding of the PAF1 sub-complex on its target genes.
Results: Depletion of PAF1 resulted in reduced tumor burden, impaired tumor sphere
formation and decreased proportions of CSCs. PAF1-depleted tumors exhibited reduced
metastatic incidence, which correlated with downregulation of CSC and metastasispromoting gene signatures in PAF1-depleted CSCs. Of significance, we found the role of
PAF1 in CSC maintenance to be independent of its PAF1C component identity. We
identified DDX3 and PHF5A as unique interacting proteins for PAF1 in CSCs and
demonstrated that the PAF1/DDX3/PHF5A sub-complex binds on the Nanog promoter, in
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turn regulating several stemness genes. Moreover, PAF1/DDX3 and PAF1/PHF5A were
co-overexpressed and co-localized in human PC tissues, human PC organoids and
mouse KPC (LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre) organoids compared to
respective controls. Strikingly, the binding of DDX3 and PAF1 on Nanog promoter, as well
as the self-renewal capacity of CSCs, were decreased following treatment with a specific
DDX3 inhibitor, RK-33. Further, several tumor-promoting pathways were significantly
downregulated in PAF1-depleted cells.
Conclusion: Overall, PAF1 functions as the master regulator for CSC maintenance in PC,
and targeting the PAF1/DDX3/PHF5A sub-complex holds promise for combating CSCmediated PC progression.
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Introduction
Despite steady increases in survival rates and improvements in patient management in
other solid malignancies, the prognosis for patients diagnosed with pancreatic cancer (PC)
remains dismal; PC has the lowest 5-year survival rate among cancers at only 9% [1]. This
is mainly due to delayed diagnosis and the inability of current therapeutic modalities to
treat this aggressive disease effectively. The current standard treatment options are
FOLFIRINOX and nab-paclitaxel-gemcitabine, which is effective in about 10-30% of cases
[2]. The vast majority of cancer recurrence is believed to be driven by sub-populations of
tumor cells with ‘stem-like’ properties and potential for tumor re-growth, which are left
unharmed by multidrug chemotherapy regimens.
Cancer cells with ‘stem-like’ properties, known as cancer stem cells (CSCs), are
responsible for tumor initiation, drug resistance, and metastases [3, 4]. The
aggressiveness of PC, its resistance to standard chemotherapy, and its ability to
metastasize have been attributed in part to a lack of effective strategies to target
pancreatic CSCs [5-7]. Several subpopulations of PC cells have been shown to be
responsible for driving tumorigenesis and mediating drug resistance, and are
characterized by the expression of CD24+/CD44+/ESA+ [8], CD133 [6], cMet [9], Nestin
[10], ALDH [11], DCLK1 [12], Musashi [13], PAF1 [14], and RORγ [15]. CSCs reactivate
embryonic features and overexpress genes associated with self-renewal and pluripotency,
such as Oct4, Sox2, Nanog, and C-Myc, particularly in more aggressive, poorly
differentiated tumors [16, 17]. Importantly, patients with low expression of CSC signatures
and markers have better prognoses than those with high expression of CSC signatures
and markers, suggesting that these tumor-initiating cells represent a high-risk population
for disease progression [18, 19]. Despite past efforts, effective strategies of targeting
CSCs are still lacking due to inadequate understanding of how these CSCs are maintained
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within the tumor [3]. Our previous work demonstrated that RNA polymerase II-associated
factor 1 (PAF1), or pancreatic differentiation 2 (PD2), is a novel CSC marker that has been
attributed to drug resistance and metastasis in PC [14, 20]. PAF1 is a core component of
human RNA polymerase II-associated factor 1 complex (PAF1C), which along with 4 other
components (LEO1, CTR9, CDC73, and SKI8) recruits RNA polymerase II for
transcriptional elongation [21, 22]. Although transcription-related roles of PAF1C have
been historically investigated, including recruitment of 3’ end-processing factors, H2B
monoubiquitination, and H3K4 di- and tri-methylation [23], recent evidence suggests it
plays a role in regulation of cell cycle progression, modulation of chromatin architecture,
and pancreatic acinar to ductal metaplasia [24-26]. The first indication of a function for
PAF1 in stem cells was from studies in mouse embryonic stem cells (ESCs), showing
PAF1 interacts with pluripotency master regulator Oct3/4, thereby facilitating self-renewal
potential [27, 28]. The recent identification of functions of PAF1 in CSCs, including
pancreatic and ovarian CSCs [14, 29], further supports this notion. In addition, PAF1 also
regulates RNA polymerase II pause release from stem cell loci [30-32]. Because
maintenance mechanisms for CSCs remain obscure, it is important to understand the
factors that support these cells, especially in PC.
We sought to decipher the mechanism by which PAF1 mediates pancreatic CSC
maintenance with the hope of uncovering strategies to target CSCs. In this study, we
established that PAF1 is critical for pancreatic tumorigenesis, and CSC-driven tumor
maintenance because depletion of PAF1 resulted in significantly less tumor burden and
fewer CSC populations. We identified that PAF1 interacts with Phf5a and DDX3, forming
a novel sub-complex that binds to the promoter region of Nanog. Several stem cell-related
genes, including GATA3, ELK1, STAT5B, STAT6, JUNB, CEBPB, CEBPA, and FOXA2,
were significantly downregulated after PAF1 depletion, in addition to loss of stemness
features. These effects appear to be independent from PAF1 function within the PAF1C,
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as CTR9, CDC73, and LEO1 were dispensable for stemness maintenance by pancreatic
CSCs and did not affect expression of CSC markers. Finally, we demonstrated that
pancreatic CSCs could be targeted with a specific DDX3 inhibitor, RK-33, with minimal
toxicity to normal pancreatic fibroblasts. Altogether, we demonstrate an important role for
PAF1 in pancreatic CSC maintenance, and we describe PAF1-regulated mechanisms of
stem cell self-renewal.

Results
A. PAF1 promotes pancreatic tumorigenesis
To determinate whether PAF1 has an effect on pancreatic tumorigenesis, we generated
a doxycycline-inducible shRNA based-knockdown system for PAF1 in PC cell lines
SW1990, HPAF/CD18, and Capan1. PAF1 knockdown was induced with doxycycline and
validated using Western Blotting (Figure 1A, Supplementary Figure 1A). Following
orthotopic implantation of engineered SW1990 cells in the pancreas of nude mice, tumor
growth was imaged via in vivo imaging systems (IVIS), and mice were randomized into
two groups: one received doxycycline to induce PAF1 knockdown and the other received
the vehicle control. PAF1 knockdown significantly impaired pancreatic tumor growth as
monitored through IVIS imaging (Figure 1B). Similarly, the mean weight of tumors derived
from PAF1-expressing control cells was significantly higher than that of PAF1-knockdown
tumors (Figure 1C). Moreover, the metastatic burdens to the liver, stomach, and intestine
were reduced upon PAF1 depletion in Capan1 xenograft tumors (Figure 1D,
Supplementary Figure 1B). Furthermore, loss of PAF1 also impaired transwell migration
and wound healing properties of PC cells (Figure 1E and Supplementary Figure 1C).
The effect of the loss of PAF1 on tumor propagation was validated using orthotopic and
subcutaneous implantation from another PC cell line, HPAF/CD18, engineered with PAF1
shRNA (CD18 sh25) (Supplementary Figure 1D, 1E). The tumors derived from the PAF1
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knockdown group exhibited much lower proliferative capacity as indicated by lower Ki67
staining (Supplementary Figure 1F). Knockdown of PAF1 in the SW1990 xenografts was
confirmed using Western Blotting (Supplementary Figure 1G). Importantly, loss of PAF1
resulted in downregulation of the self-renewal markers Nanog and Sox9 (Supplementary
Figure 1H). The CSC model of tumor propagation proposes that CSCs are capable of
initiating tumor growth and propagation in immunocompromised mice [33]. Histologically,
CSCs have been identified by expression of putative CSC markers (CD44v6, CD24, ESA,
and ALDH1), expression of self-renewal proteins (Sox2, Oct3/4, β-CATENIN, NANOG and
SOX9), and functional characteristics such as drug resistance, autofluorescence, and
expression of aldehyde dehydrogenase [34, 35]. We have previously demonstrated that
PAF1 is overexpressed in pancreatic and ovarian CSCs [14, 23, 29], indicating its possible
role in CSC maintenance. Therefore, we evaluated the effect of PAF1 depletion on CSC
maintenance through analysis of CSC markers and proportion of CSC populations. We
found that PAF1 depletion led to a significant reduction in expression of established CSC
markers, such as CD24, CD44v6, and ALDH1, and the self-renewal markers SOX2,
OCT3/4, β-CATENIN, and SOX9 (Figure 1F, Supplementary Figure 1I). Additionally,
PAF1 depletion caused a significant reduction in the percentage of CD44+ CSCs (Figure
1G, Supplementary Figure 1J), indicating that the effect of PAF1 abrogation on
tumorigenesis could involve its role in CSC maintenance. Furthermore, we also observed
a significant decrease in percentage of ALDH1+ CSCs (Supplementary Figure 1K) and
side population (SP) cells (Supplementary Figure 1L). These results collectively indicate
that PAF1 plays a cardinal role in pancreatic tumorigenesis possibly via affecting CSC
maintenance.
B. PAF1 is overexpressed in CSCs and maintains pancreatic CSCs
To evaluate the role of PAF1 in CSC maintenance, we used the SP assay, a technique
for isolation of CSCs based on the efflux of DNA-binding soluble dyes such as Hoechst

80

33342, to obtain CSCs from PC cells (Supplementary Figure 2A) [29]. Isolated SP
(putative CSCs) and non-side population (NSP) cells were evaluated for expression of
CSC and self-renewal markers using immunoblotting. PAF1 was significantly
overexpressed in SP (CSCs) isolated from PC cell lines SW1990 and Capan1 compared
to NSP cells (non-CSCs) (Figure 2A). Isolated CSCs expressed higher levels of
established CSC markers, including ESA, CD44, CD44v6, CD24, CD133, and ALDH1
(Figure 2A). Similarly, CSCs expressed higher levels of self-renewal markers, such as
SOX2, SOX9, OCT3/4, and β-CATENIN, compared to non-CSCs (Figure 2B). SW1990
and Capan1 SP cells formed a significantly greater number of tumor spheres in vitro
(Supplementary Figure 2B) compared with NSP cells. Orthotopic implantation of
SW1990 SP cells resulted in much larger tumors than NSP cells (Supplementary Figure
2C), validating the purity of isolated CSCs and non-CSCs. To test the importance of PAF1
in CSC maintenance, we depleted PAF1 from SW1990 SP and Capan1 SP cells using
CRISPR/Cas9 and doxycycline-inducible shRNA. Depletion of PAF1 caused a significant
downregulation of CSC markers ALDH1 and CD44v6, and of self-renewal markers SOX9
and β-CATENIN at the RNA (Supplementary Figure 2D) and protein levels (Figure 2C).
We further confirmed the effect of PAF1 loss on CSC and self-renewal markers through
dual confocal microscopy. In control CSCs, PAF1 is co-overexpressed with CSC markers
(ALDH1 and CD44v6) and self-renewal proteins (β-CATENIN and SOX9), whereas these
markers are significantly decreased upon PAF1 depletion (Supplementary Figure 2E).
Using an ALDEFLUOR assay to measure the aldehyde dehydrogenase activity of cells,
considered a functional CSC trait [11], we observed a significant decrease in the
percentage of ALDH+ cells in SW1990 SP PAF1 knockdown cells compared to CSCs with
endogenous PAF1 expression (Figure 2D). Depletion of PAF1 also affected the selfrenewal capacity and proliferation of CSCs, as indicated by impaired in vitro tumor sphere
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formation (Figure 2E and Supplementary Figure 2F) and reduced colony formation
ability (Supplementary Figure 2G). These results collectively indicate that PAF1 is
required for self-renewal and maintenance of CSCs.
C. Role of PAF1 in pancreatic CSC maintenance independent from PAF1C function
To determine whether PAF1-mediated CSC maintenance involves PAF1C, we assessed
the contribution of each subunit of PAF1C to maintenance of the CSC state. First, we
evaluated the expression of PAF1 and other PAF1C subunits in human PC tissues and
normal pancreas tissues using the GEPIA database. PAF1 and other PAF1C subunits
(LEO1, CTR9, and CDC73) exhibited significantly higher expression in tumor tissues
compared to normal tissues (Supplementary Figure 3A). Next, we determined the
expression of other PAF1C subunits in isolated CSCs (SP cells) and non-CSCs (NSP
cells). Intriguingly, expression of CTR9, LEO1, and CDC73 did not vary between SP and
NSP cells from SW1990 and Capan1 (Figure 3A). Furthermore, we evaluated the effect
of individual knockdown of each of the PAF1C subunits on expression of CSC markers
(ESA, CD44v6, β-CATENIN, and SOX9) and found no significant changes (Figure 3B),
indicating that these PAF1C members likely do not affect pancreatic CSC maintenance
individually. Of importance, individual knockdown of CTR9, LEO1, and CDC73 did not
impair the ability of CSCs to form tumor spheres (Figure 3C). Comparing expression of
different PAF1C subunits in high purity tumor tissues from The Cancer Genome Atlas,
PAF1 displayed the highest expression compared to other PAF1C subunits
(Supplementary Figure 3B). Previously, we reported that PAF1 is essential for
maintenance of pluripotency of mouse ESCs[28]. Our previous study showed that
knockdown of PAF1 in differentiated cells, such as NIH 3T3 cells, decreased expression
of other PAF1C members (CTR9, LEO1, and CDC73). However, loss of Paf1 from mouse
ESCs did not affect the expression of other PAF1C components, indicating an
uncoordinated expression pattern in stem cells [28]. This observation prompted us to
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investigate the effect of PAF1 depletion on other PAF1C members in CSCs, since similar
stemness properties are shared with ESCs. In line with our observations in ESCs,
depletion of PAF1 from SP cells (CSCs) did not affect the expression of other PAF1C
components (Figure 3D). However, downregulation of PAF1 in NSP cells decreased
expression of other PAF1C subunits (Figure 3D), indicating a differential regulation of
PAF1C in CSCs versus non-CSCs. Interestingly, individual knockdown of LEO1, CTR9,
and CDC73 significantly downregulated other PAF1C subunits including PAF1 (Figure
3E).
D. PAF1-PHF5A sub-complex regulates the stem cell state in pancreatic CSCs
Based on our findings of differential regulation of PAF1 in CSCs and non-CSCs, we
hypothesized that PAF1’s role in CSC maintenance requires interaction with other
proteins. The first candidate we explored was PHD finger protein 5a (PHF5A), a nuclear
protein that regulates pluripotency in ESCs[32]. PHF5A has been shown to be a stabilizing
protein for PAF1C in mouse ESCs and is known to regulate RNA polymerase II elongation
at pluripotency loci [32]. PHF5A exhibited significant upregulation in PC patient tissues
compared to normal pancreas tissues (Supplementary Figure 4A). Given the similarities
between ESCs and CSCs, we investigated the status of PHF5A in SP and NSP cells and
found that PHF5A is overexpressed in SP compared to NSP cells isolated from SW1990
and Capan1 (Figure 4A). Further, PAF1 and PHF5A co-localized in the nucleus of CSCs,
as observed using confocal microscopy, whereas minimal expression was detected in
SW1990 NSP (non-CSCs) cells (Figure 4B and Supplementary Figure 4B). Using
reciprocal co-immunoprecipitation, we observed that PAF1 interacts with PHF5A (Figure
4C). Of interest, the PAF1C subunits LEO1, CTR9, and CDC73 interacted with PAF1 in
CSCs, but not with PHF5A (Figure 4C). We observed that PAF1 colocalized with PHF5A
in distinct cells from human PC tumor tissues, alluding to the clinical significance of their
interaction (Supplementary Figure 4C). These results suggest that PAF1 possibly forms

83

a sub-complex with PHF5A and other proteins, which does not include LEO1, CTR9, and
CDC73.
To determine the functional relevance of PHF5A for maintenance of pancreatic
CSCs, we investigated the effect of PHF5A loss on expression of CSC markers.
Surprisingly, most established CSC markers, including CD133, ESA, SOX9, OCT3/4, βCATENIN, and PAF1, were not affected (Figure 4D). Thus, we used a global approach to
identify the genes that are jointly regulated by PAF1 and PHF5A by performing chromatin
immunoprecipitation sequencing (ChIP-Seq) with PAF1 and PHF5A-pulldown in CSCs
(SW1990 SP cells). Chromosome-wide PAF1 peaks were more frequent than PHF5A
peaks in SW1990 SP cells, at a false discovery rate of less than 0.05 (Supplementary
Figure 4D), potentially explaining why PAF1 depletion had a greater effect on CSC
markers compared with PHF5A depletion. Promoters of several stemness regulators,
including Nanog, SOX9, ABCB5, ERBB2, LIF, POU5F1 and others, were occupied by
PAF1 and PHF5A in SW1990 SP cells (Figure 4E). Nanog was amongst the top genes
whose promoters were jointly occupied by PAF1 and PHF5A in SW1990 SP cells.
Furthermore, PAF1 and PHF5A occupied the Nanog promoter at identical loci (Figure
4F). For subsequent analyses, we focused on Nanog, as it is the master regulator for
pluripotency and stem cell state[36]. Knockdown of PAF1 and PHF5A led to significant
downregulation of Nanog, as observed by immunoblot and qRT-PCR analysis (Figure 4G
and Supplementary Figure 4E). Importantly, knockdown of PAF1 and PHF5A also
reduced nuclear localization of Nanog in CSCs, observed by confocal microscopy (Figure
4H).
E. PAF1 sub-complex interacts with DDX3 to regulate Nanog transcriptionally
To identify additional interacting partners of PAF1 in pancreatic CSCs, we performed mass
spectrometry using immunoprecipitation of PAF1 from pancreatic CSCs (SW1990 SP
cells), a mouse pluripotent stem cell (embryonic carcinoma) line (F9), and a pancreatic
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ductal cell line (HPDE). Several unique interaction partners for PAF1 were identified in
addition to the canonical PAF1C members (LEO1, CTR9, CDC73, and SKI8). Proteins
identified as common interactors of PAF1 in pancreatic CSCs and ESCs are HNRPM,
EWS, RL4, RS2, RL7, HNRPK, DYHC1, SFPQ, RS6, RL12, RL3, RL11, EF2, RL15,
LASP1, EFTU, IMA1, DDX3X, and SRSF3 (Figure 5A). These proteins might be a part of
the PAF1 sub-complex and facilitate effects on pancreatic CSC stemness. Of these 19
proteins, DDX3 showed the highest probability of interaction with PAF1 in SW1990 SP
and F9 cells, which was validated using co-immunoprecipitation (Figure 5B,
Supplementary Figure 5A). DDX3 is an RNA helicase, which facilitates unwinding RNA
secondary and tertiary structures and is therefore involved in multiple aspects of RNA
metabolism. Emerging evidence indicates that DDX3 can participate in the epithelial-tomesenchymal transition (EMT), apoptosis, cell cycle regulation, and tumorigenesis[37-39].
We found DDX3 was overexpressed in human PC tumors compared to normal tissues
(Supplementary Figure 5B), in oncogene-transduced HPNE cells (E6/E7/Htert/KRAS
HPNE versus HPNE control), and in CSCs compared to non-CSCs (Figure 5C). Using
dual confocal microscopy, we found co-localization of PAF1 and DDX3 in specific cells
within human PC tissues, PC patient tissue-derived organoids, and KPC (LSL-KrasG12D/+;
LSL-Trp53R172H/+; Pdx-1-Cre) mouse organoids, while PAF1 and DDX3 showed basal
expression in respective normal tissues and did not co-localize (Figure 5D, E, and
Supplementary Figure 5C). Moreover, DDX3 and PAF1 were co-overexpressed in
SW1990 SP cells compared to NSP cells (Figure 5F, Supplementary Figure 5D). To
determine whether DDX3 was a part of PAF1-PHF5A sub-complex, we investigated if
DDX3 and PHF5A interact. We found an interaction of DDX3 and PHF5A in SW1990 SP
cells (Figure 5G), indicating the existence of a ternary complex composed of PAF1,
PHF5A, and DDX3. Importantly, DDX3 was found to bind to a specific region of the Nanog
promoter (Figure 5H), indicating that the PAF1/PHF5A/DDX3 sub-complex regulates
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Nanog. Consistent with roles of Nanog and PAF1 in CSC maintenance, we observed cooverexpression of PAF1 and Nanog in human PC tissues compared to normal pancreas
(Supplementary Figure 5E) and poorer survival in patients with higher expression of
Nanog (Supplementary Figure 5F). Collectively, these results demonstrate that the
PAF1/PHF5A/DDX3 sub-complex regulates Nanog in pancreatic CSCs, with potential
clinical relevance.
F. Abrogation of DDX3 activity impairs cancer stem cell maintenance
Since we found a role of the PAF/PHF5A/DDX3 sub-complex in pancreatic CSC
maintenance, we next sought to determine a means of disrupting this sub-complex to
target CSCs. To this end, we investigated the effect of RK-33, a specific small molecule
inhibitor of DDX3 helicase activity. RK-33 action on DDX3 and its anti-tumor activity has
previously been investigated in lung cancer and Ewing sarcoma [40, 41]. To the best of
our knowledge, RK-33 has not been tested on PC cells. Of importance, CSCs (SW1990
SP and Capan1 SP) were more sensitive to RK-33 than normal human fibroblast cells
(IC50 in 9-26 NP fibroblasts was 1.5- to 2-fold higher than that of SW1990 SP and Capan1
SP; SW1990 SP: 4.32 μM; Capan1 SP: 5.53 μM; 9-26 NP: 9.23 μM) (Supplementary
Figure 6A). Treatment of CSCs with RK-33 for 48 h led to a significant downregulation of
CSC markers (β-CATENIN, CD44v6, SOX9, and NANOG) (Figure 6A). To our surprise,
we found a robust downregulation of PAF1 with RK-33 treatment (Figure 6A). Further, the
effect of RK-33 on expression of CSC markers in NSP cells (non-CSCs) was not as
profound as that seen with SP cells (CSCs) (Supplementary Figure 6B). Functionally,
DDX3 inhibition impaired the tumor sphere formation capacity (Figure 6B) and colony
formation ability (Supplementary Figure 6C) of CSCs. Additionally, treatment with RK33 resulted in apoptosis of CSCs (Supplementary Figure 6D, 6E), while minimal cell
death was seen in normal human fibroblasts (9-26 NP), supporting the clinical applicability
of RK-33. It is important to note that both PAF1 and DDX3 were found to bind on the
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Nanog promoter, and treatment with RK-33 decreased their binding significantly (Figure
6C). Furthermore, we validated downregulation of PAF1 and Nanog expression following
RK-33 treatment using qPCR (Figure 6D). Knockdown of DDX3 in CSCs phenocopied
the effects observed with RK-33 treatment, causing downregulation of CSC markers
CD44v6, β-CATENIN, SOX9, and NANOG (Figure 6E).
G. Stemness and metastasis-promoting genes are targets of PAF1
To identify targets of PAF1 in CSCs, control and PAF1 knockdown CSCs were used for
analyzing expression of human transcription factors using a PCR array. Several genes
with known functions in stemness (Gata3, Elk1, Stat3, Stat5b, Stat6, Jun-B, Cebpb,
Cebpa, Ctnnb1, Crebbp, and Foxa2) were significantly downregulated (Figure 7A). Other
transcription factors that were significantly upregulated included Hnf4a and Foxg1.
Ingenuity pathway analyses revealed that several stemness and tumor-promoting
pathways, including JAK/STAT signaling, IL-6 signaling, ERK/MAPK signaling, and
CXCR4 signaling, were significantly downregulated, and ADCY4, MAPK10, JUN, CEBPB,
STAT2, STAT6, STAT5B, JUNB, JUND, ELK1, CREBBP, and CTNNB1 were identified as
candidate players in these pathways (Figure 7B). These signaling pathways play
essential roles in proliferation and tumorigenesis and in mediating metastasis, and
therefore further corroborate the importance of PAF1 in CSC maintenance. On a global
scale with RNA sequencing, we observed 188 downregulated genes and 73 upregulated
genes upon PAF1 depletion in CSCs. Of importance, genes with important roles in
stemness maintenance (Flot2, Taz, Epcam, Erbb2, Foxp1, Abcc5, Ddr1, Muc1, Pecam1,
Notch3, Aldh1a3, Foxa2, Plat, and Lif) and metastasis (Itga3, St6galnac4, Flot1, S100a14,
Mmp14, Flot2, Itgb2, S100a9, St6galnac2, S100a11, Muc1, Itgb7, and St6galnac1) were
significantly downregulated (Figure 7C and Supplementary Figure 7A). Given that CSCs
mediate tumor relapse, we evaluated the expression of genes associated with relapse in
control and PAF1-depleted CSCs and found significant downregulation of relapse genes
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such as Sema3b, Abcc5, Fgfr3, Tspan1, Muc1, Tff1, Ephb2, Alcam (Supplementary
Figure 7B).Comparing PCR array and ChIP-sequencing data, we found a greater
enrichment of PAF1 on promoters of those genes that were downregulated on PAF1
knockdown (Supplementary Figure 7C). Overall, these data indicate that PAF1 functions
as the master regulator for stem cell maintenance by regulating transcription of several
stem cell-related genes.

Discussion
Previous work from our laboratory and others has demonstrated that PAF1 is essential in
normal stem cell maintenance [27, 28]. In addition, a role for PAF1 in the self-renewal of
CSCs in pancreatic and ovarian cancer has recently been established [14, 23, 29]. While
these studies point to the importance of PAF1 in stem cells, little was understood about
how PAF1 mediates these CSC functions. In this study, we mechanistically established
PAF1 as an essential regulator of CSC maintenance in PC and demonstrated the
existence of a unique sub-complex of PAF1, PHF5A and DDX3 in CSCs. Using different
strategies to downregulate PAF1 in several PC cell lines, we demonstrated that PAF1
depletion led to decreases in CSC markers, CSC frequency, stemness features, and
tumor burden. PAF1 ablation downregulated CSC gene expression signatures, and PAF1
was found to bind on several stem cell gene promoters in pancreatic CSCs. PAF1C has
been connected to both activating and repressing effects on gene transcription, depending
on the cellular context [30, 31, 42]. In our system, we have focused on activating functions,
as our ChIP-seq analysis revealed a strong binding of PAF1 at CSC genes that were
significantly downregulated upon PAF1 depletion. Nevertheless, it would be interesting to
address the repressive functions of PAF1 in pancreatic CSCs.
We showed that PAF1 downregulation impaired the formation of pancreatic tumors
in orthotopic and subcutaneous models using multiple cell lines. Further, we found PAF1
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depletion significantly decreased various CSC populations (CSCs with high expression of
CD44, cells with high ALDH activity, and SP cells) and expression of CSC markers,
suggesting that the decreased tumorigenesis on PAF1 depletion is, in part, due to the role
of PAF1 in CSC maintenance. Similar to previous reports[14, 23], we found PAF1 to be
overexpressed in CSCs and important for regulating the expression of CSC markers and
phenotypic features of CSCs. Although we found an upregulation of LEO1, CTR9, and
CDC73 transcripts in human pancreatic tumor samples compared to normal pancreas,
these other PAF1C subunits were not overexpressed in isolated CSCs. Interestingly, the
other PAF1C subunits, LEO1, CTR9, and CDC73, appear dispensable for the
maintenance of stem cell state, as their downregulation affected neither the expression of
CSC markers nor the formation of tumor spheres. This reiterates the idea that PAF1C
subunits may play PAF1C-independent roles. For instance, the PAF1C subunit CTR9 has
been shown to regulate ERα+ breast tumorigenesis and control morphology, proliferative
capacity, and tamoxifen sensitivity of luminal breast cancer cells, while no other PAF1C
subunit except PAF1 could modulate these features [43]. Similarly, CDC73, another
PAF1C subunit, was recently shown to play an indispensable role in maintaining mouse
hematopoietic stem cells and in regulating leukemia-specific gene programs [44]. In the
aforementioned study, the authors demonstrated that a loss of CDC73 resulted in distinct
transcriptional changes in hematopoietic stem/progenitor cells and leukemic cells,
suggesting that PAF1C controls unique gene programs in normal versus malignant cells.
This is in line with our observation of differential expression of PAF1C subunits in CSCs
(SP) versus non-CSCs (NSP) following PAF1 loss. We postulated that PAF1 achieves
cell-type-specific functions based on the availability of its interacting partners. In line with
this, PAF1 interacts with another pluripotency regulator, PHF5A, in ESCs and in turn
regulates RNA polymerase II pause-release of pluripotency genes in ESCs [32]. In this
study, Strikoudis et al. demonstrated that the interaction of PAF1 with PHF5A maintained
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the stability of PAF1C in ESCs [32]. Although PHF5A was found to interact with other
PAF1C members in ESCs; it only interacts with PAF1 and not LEO1, CTR9, or CDC73 in
pancreatic CSCs. Furthermore, the treatment of NSP cells with DDX3 inhibitor (RK-33)
had limited effects on expression of CSC markers, in contrast to the effects observed in
SP cells. This reiterates that the PAF1 sub-complex with DDX3 and PHF5A is unique to
CSCs.
A previous report showed that MED12, a member of a transcriptional complex,
maintained stem/progenitor cells of the hematopoietic system by regulating hematopoietic
stem cell-specific enhancers, independently of its kinase role [45]. By contrast, we found
that PAF1, along with its binding partners, regulates the promoters of stem cell genes.
PAF1 has been suggested to modulate metazoan gene expression by several means,
including modulation of the RNA polymerase II paused state and enhancer activation, in
addition to its direct roles in transcription elongation [30, 31, 42]. For instance, PAF1 has
been implicated in restraining full activation of a subset of enhancers and consequently
impairs the release of paused RNA polymerase II from nearby target genes in colorectal
carcinoma HCT116 cells [31]. However, it would be interesting to be see if PAF1 is
required for hyperactivation of stem cell enhancers in pancreatic CSCs.
In contrast to PAF1, which had a profound effect on stem cell gene regulation,
PHF5A depletion altered the expression of NANOG, but not other known CSC markers.
This observation was supported by our ChIP-Seq analysis wherein chromosome-wide
binding for PAF1 was more frequent compared to PHF5A. However, Nanog emerged as
the common target of PAF1 and PHF5A in pancreatic CSCs. Although Nanog is
considered a stem cell master regulator, it is now known to be de-repressed in several
cancers, including breast [36], ovarian [46], lung [47], colorectal [48], pancreatic [49], and
others [50, 51]. A body of literature suggests that the drug-resistant cancer cells
responsible for tumor recurrence express Nanog following conventional treatment [52-54].

90

CSCs expressing Nanog have been targeted with inhibitors and shRNA; more recently,
the use of dendritic cell vaccination against NANOG has been suggested [55-57]. These
studies emphasize the clinical and functional significance of Nanog for CSC maintenance
and underscore the relevance of our findings. Of importance, we demonstrated colocalization of PAF1 and NANOG in human pancreatic tumor tissues and loss of NANOG
expression upon PHF5A and PAF1 depletion in pancreatic CSCs.
We identified DDX3 as a novel binding partner of PAF1 in pancreatic CSCs. It
belongs to the DEAD box family of RNA helicases, which have primary roles in unwinding
complex RNA secondary and tertiary structures. However, several members of this family
additionally function in transcriptional regulation[58-60]. RNA helicase DDX3 is involved
in transcription, RNA splicing, nuclear export of mRNA, and translation initiation [37, 61,
62]. We showed that PAF1 and DDX3 play a role in the maintenance of pancreatic CSCs.
Inhibition of DDX3 activity by RK-33 downregulated CSC markers and PAF1, while a loss
of DDX3 alone had a similar effect on expression of CSC markers. This indicates that
DDX3 alone may have important roles in CSC biology. This notion is supported by a recent
publication that showed DDX3 is overexpressed in undifferentiated human ESCs
compared to differentiated cells, and that perturbation of DDX3 activity reduced
expression of the pluripotency regulators OCT4, SOX2, and NANOG and impaired
teratoma formation [63]. Importantly, we demonstrated that RK-33 treatment reduced
localization of DDX3 and PAF1 on the Nanog promoter.
We finally show that PAF1 depletion downregulated stem cell-related transcription
factors and genes, including JAK/STAT, ERK/MAPK, and CXCR4 signaling pathways.
The role of PAF1 in regulating these stem cell genes is indicated by its localization on
promoters of these genes. Several of these pathways are also drivers of tumorigenesis.
For instance, several studies have shown the importance of the JAK/STAT pathway,
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particularly STAT3 activation in mediating tumorigenic ability of CSCs in breast [64], colon
cancer [65], and several other cancers [66]. STAT3 is constitutively active in PC [67] and
plays a role in proliferation, survival and metastasis of pancreatic tumor cells [68-70].
Additionally, the STAT3/Sox2 axis has been documented to play an important role in
maintaining stem cell phenotypes in PC cells [71]. Similarly, PAF1 knockdown
downregulated pathways involved in CSC-mediated cancer pathogenesis including
CXCR4[6] and Wnt/β-catenin signaling [72]. Together, these observations underscore the
pivotal role of PAF1 in mediating stemness and indicate that PAF1 may serve as a
common upstream regulator of these pathways. Given that PAF1 has multiple functions
and serves as a converging point for several co-transcriptional processes, including
transcription elongation, termination, and mRNA processing, its basic functions in different
cell types and disease settings merit further study. Nonetheless, this study serves as a
stepping-stone for targeting PAF1-dependent pancreatic CSC maintenance through
DDX3. Taken together, these data reveal that the PAF1/PHF5A/DDX3 sub-complex is
required for sustenance of pancreatic CSCs (Figure 7D) and present a therapeutic
window to target this sub-complex through DDX3 inhibition.
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Figure Legends
Figure 1: Loss of PAF1 reduces pancreatic tumorigenesis and proportions of CSCs.
A. Immunoblot depicting the efficiency of PAF1 knockdown (KD) using a doxycyclinebased inducible shRNA system. B. Representative IVIS image of mice from control and
PAF1 KD group. Right panel represents quantification of total photon counts at indicated
time points. Data represented as mean ± SD (n = 10 mice per group). C. Representative
images and quantification of tumor weights generated with orthotopic implantation of
engineered SW1990 and Capan1 cells in pancreas of athymic nude mice. D. Graphical
representation of metastatic incidence in xenografts generated from orthotopic
implantation of control and PAF1-depleted Capan1 cells. E. Quantification of the average
number of migrating cells in control and PAF1-depleted SW1990 cells. Representative
images are shown on the right. Scale bars are 1000 μm. Data representative of three
independent experiments. F. Immunoblot analysis of PAF1 and CSC markers (CD24,
CD44v6, and ALDH1) and self-renewal markers (β-CATENIN, SOX9, SOX2, and OCT3/4)
with and without doxycycline treatment in engineered SW1990 and Capan1 cells. G.
Percentage of high CD44+ cells in control and PAF1 KD SW1990 and Capan1 cells. *P
<0.05, **P <0.01, ***P <0.001.
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Figure 2: PAF1 is upregulated in pancreatic CSCs and is required for sustenance of
CSCs. A. Immunoblot analysis depicting the expression of PAF1 and CSC markers in
isolated CSCs (SP cells) from SW1990 and Capan1 compared to non-CSCs (NSP cells).
B. Immunoblot analysis representing variation in expression of self-renewal markers
between NSP and SP cells. C. Immunoblot analysis depicting the effect of depletion of
PAF1 in CSCs on CSC (CD44v6 and ALDH1) and self-renewal markers (β-CATENIN and
SOX9). D. Representative scatter plots and quantification of percentage of ALDH+ cells in
control versus PAF1-depleted CSCs. E. Representative images of tumor spheres and
quantification of number of tumor spheres generated by control versus PAF1 KD CSCs.
Scale bars are 1000 μm. Data is represented as mean ± SEM. *P <0.05, **P <0.01, ***P
<0.001.
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Figure 3: LEO1, CTR9, and CDC73 are not major contributors to CSC maintenance.
A. Immunoblot analysis of PAF1C subunits in SP and NSP cells. Equal amounts of protein
were loaded in each well. B. Immunoblot analysis of CSC markers (ESA and CD44v6)
and self-renewal markers (β-CATENIN and SOX9) with individual knockdown of CDC73,
CTR9, and LEO1. C. Average number of tumor spheres formed with individual knockdown
of LEO1, CDC73, and CTR9 at 0 h and 96 h. Data representative of two independent
experiments and three replicates per condition. D. Immunoblot analysis of PAF1C
subunits (CTR9, LEO1, and CDC73) with PAF1 depletion in SP and NSP cells. E.
Immunoblot analysis of PAF1C subunits with individual loss of CTR9, LEO1, and CDC73.
n.s. = non-significant.
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Figure 4: PAF1 interacts with PHF5A and jointly regulates Nanog. A. Immunoblot
analysis of PHF5A in SW1990 and Capan1 SP and NSP. B. Representative
immunofluorescence image of PAF1 and PHF5A representing co-localization in nuclei of
isolated CSCs. Data representative of three independent experiments and quantification
is shown in supplementary Figure 4B. C. Immunoprecipitation was performed with PAF1
and PHF5A antibodies from SW1990 SP, and immunoblotting was performed for PAF1,
PHF5A, CTR9, LEO1, and CDC73. D. Immunoblot analysis of CSC markers (CD133,
ESA, and PAF1) and self-renewal markers (SOX9, β-CATENIN, and OCT3/4) with
depletion of PHF5A in SW1990 SP cells. E. Heatmap of mean binding enrichment of PAF1
and PHF5A on promoters of stem cell genes. F. Representative examples of UCSC
genome browser tracks of PAF1 and PHF5A ChIP-Seq in SW1990 SP cells. G.
Immunoblot analysis of Nanog with PAF1 and PHF5A depletion. H. Immunofluorescence
analysis of PHF5A and NANOG in SW1990 SP cells with depleted PHF5A. Quantification
of mean florescence intensity (MFI) is shown on the right. Lower panel shows expression
of PAF1 and NANOG in control and PAF1-depleted SW1990 SP cells. Data representative
of two independent experiments and is presented as a mean of five individual images per
condition. *P <0.05, **P <0.01, ***P <0.001.
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Figure 5: Mass spectrometric analysis identified RNA helicase DDX3 as a novel
interacting partner of PAF1. A. Venn diagram depicting percentage of interacting
proteins of PAF1 in F9, HPDE, and SW1990 SP cells. Common interacting proteins are
listed. B. Reciprocal immunoprecipitation analysis of PAF1 and DDX3 in SW1990 SP and
HPDE cells. C. Immunoblotting analysis of DDX3 in NSP and SP cells isolated from
SW1990 and Capan1 and in control versus E6/E7/Htert/KRAS HPNE cells. D.
Immunofluorescence analysis of PAF1 and DDX3 in human PC tissues and normal
pancreas. White arrows indicate individual cells with co-localized PAF1 and DDX3. E.
Immunofluorescence images showing co-localization of PAF1 and DDX3 in human PC
organoids and mouse KPC organoids. Representative images depicting expression of
PAF1 and DDX3 in human and mouse normal organoids are shown in lower panel. F.
Representative immunofluorescence image depicting expression of PAF1 and DDX3 in
SW1990 SP cells and SW1990 NSP cells. Quantification is shown in Supplementary
Figure 5C. G. Immunoprecipitation analysis of PHF5A and DDX3 in SW1990 SP followed
by immunoblotting for PHF5A. H. Representative ChIP-PCR gel images demonstrating
DDX3 binding on binding site 4 (B.S. 4) on Nanog promoter. Primers specific for B.S. 1
and B.S. 8 did not amplify. Primer sequences are shown in Supplementary table 1.
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Figure 6: DDX3 inhibition downregulates CSC markers and decreases binding on
Nanog promoter. A. Immunoblotting analysis for DDX3, PAF1, CD44v6, NANOG, SOX9,
and β-CATENIN following RK-33 treatment for 48 h. B. Representative images of tumor
spheres in control and RK-33 (2.5 μM)-treated SW1990 SP cells. 1000 cells were seeded.
Treatment was performed 24 h after seeding and images were taken 14 days following
treatment. Quantification of the average number of tumor spheres is shown on the right
and is represented as mean ± SEM. Data representative of two independent experiments
and six replicates per condition. Scale bars are 1000 μm. C. ChIP-PCR gel images for
PAF1 and DDX3 using primers specific for B.S. 4, B.S. 1, and B.S. 8 in DMSO- and RK33 (5 μM)-treated SW1990 SP cells. ChIP qRT PCR analysis of PAF1 and DDX3 using
B.S. 4 primers in DMSO- and RK-33 (5 μM)-treated SW1990 SP cells is represented on
right. Data representative of three independent experiments. D. Quantification of PAF1
and Nanog transcripts in DMSO- and RK-33-treated CSCs. Data representative of three
independent experiments and error bars indicate SEM values. E. Immunoblotting analysis
for DDX3, PAF1, CD44v6, NANOG, and β-CATENIN in control and DDX3-knockdown
CSCs. *P <0.05, **P <0.01, ***P <0.001.
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Figure 7: PAF1 behaves as the master regulator of stem cell maintenance. A. RT2
profiler PCR array analysis of human transcription factors in SW1990 SP control and
PAF1-depleted cells. Upregulated genes are indicated in red, and genes significantly
downregulated upon PAF1 depletion are indicated in green. Genes encircled in red were
validated using qRT PCR. B. Representative network of significantly downregulated
pathways upon PAF1 loss in SW1990 SP cells, derived from ingenuity pathway analysis
of downregulated genes from PCR array and RNA-Seq. C. Heatmap representing genes
significantly downregulated upon PAF1 depletion in CSCs, and expression pattern of
stemness genes in control and PAF1-depleted CSCs. D. Schematic illustration of
mechanism of PAF1-mediated maintenance of pancreatic CSCs. PAF1, PHF5A, and
DDX3 are upregulated in PC and form a sub-complex that supports pancreatic CSCs.
Depletion of PAF1 results in decreased percentage of CSCs, reduced tumorigenesis and
impaired tumor sphere formation.
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Supplementary Figure Legends
Supplementary Figure 1: Loss of PAF1 reduces pancreatic tumorigenesis and
proportions of CSCs. A. Immunoblot analysis for PAF1 in CD18 cells representing
efficiency of PAF1 knockdown. B. Representative H and E demonstrating histology of
pancreas tumor and metastases to liver, intestine, and stomach for control and PAF1depleted Capan1 xenograft tumors. Scale bars are 1000 μm. C. Graphical representation
of percentage wound closure after 24 h in control and PAF1 depleted SW1990 cells.
Representative images are shown on right. Data representative of three independent
experiments and error bars show mean ± S.E. Scale bars are 1000 μm. D. Mean tumor
weight in control and PAF1 knockdown group generated from orthotopic implantation of
CD18 cells in pancreas of nude mice. Representative image is shown below. Tumors were
harvested 6 weeks following implantation. N = 10 mice per group. E. Graphical
representation of mean tumor weight of control and PAF1-depleted CD18 tumors
generated with subcutaneous implantation. Tumors were harvested 6 weeks following
implantation. Representative images are shown below. N = 4 mice per group. Both right
and left flank were used for implantation. F. Representative immunohistochemistry images
of Ki67 expression in control and PAF1 depleted SW1990 xenograft tumors. Scale bars
are 1000 μm. G. Immunoblot analysis of PAF1 from SW1990 control and PAF1
knockdown xenograft tumors. β-ACTIN was used as a loading control. H. Immunoblot
analysis of Paf1, Nanog, and Sox9 in PAF1 depleted pancreatic tumors obtained from
orthotopic implantation of SW1990 cells. I. Immunoblot analysis of PAF1, CSC markers
(CD44v6, ALDH1, and Lgr5), and self-renewal markers (β-CATENIN and SOX9) upon
PAF1 depletion in CD18 cells. J. Percentage of high CD44+ cells in control and PAF1
depleted CD18 cells. Data representative of three independent experiments.
Representative histogram from one experiment is shown on right. K. Representative
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scatter plots and quantification of number of ALDH1+ cells upon PAF1 depletion in CD18
cells. Data representative of three independent experiments. L. Quantification of
percentage of SP cells upon PAF1 knockdown in CD18 cells. Representative scatter plots
are on left. Data representative of three independent experiments. *P <0.05, **P <0.01,
***P <0.001.
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Supplementary Figure 1 Cont.
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Supplementary Figure 2: PAF1 is upregulated in pancreatic CSCs and is required
for sustenance of CSCs. A. Flow sorting of SP and NSP cells from SW1990 and Capan1
cells. B. Representative images depicting number and size of tumor spheres formed by
SP and NSP cells from SW1990 and Capan1. Graphical representation of average
number of tumor spheres per 1000 cells (mean ± SEM) is shown on the right side. Six
replicates per cell line were used. The images were taken two weeks after seeding cells.
Scale bars are 1000 μm. C. Representative necropsy image of nude mice orthotopically
injected with SW1990 SP and NSP cells. 100 cells were injected, and mice were
euthanized 4 weeks following implantation. D. Quantification of PAF1, CD44v6, ALDH1,
β-Catenin, and Sox9 transcripts in control and PAF1 depleted CSCs. Data representative
of three independent experiments. Primer sequences are shown in Supplementary table
2. E. Immunofluorescence analysis of PAF1, CSC markers (ALDH1 and CD44v6), and
self-renewal markers (β-CATENIN and SOX9) in control and PAF1 depleted CSCs.
Quantification of MFI is shown on the right. Error bars indicate mean ± S.D. Scale bars
are 20 μm. F. Quantification of diameter of tumor spheres generated by control CSCs
versus PAF1 KD CSCs. G. Quantification of total colony area and representative images
of colonies formed by control and PAF1 knockdown CSCs. Data representative of three
independent experiments and error bars indicate SEM values. *P <0.05, **P <0.01, ***P
<0.001.
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Supplementary Figure 2 Cont.

113

Supplementary Figure 2 Cont.
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Supplementary Figure 3: Expression variation of PAF1 and other PAF1C subunits
in human PC cases compared to normal pancreas. A. Box plots representing the
mRNA expression profiles of PAF1C subunits (PAF1, LEO1, CTR9, and CDC73) across
179 PC cases (TCGA-PAAD data) and 171 normal pancreas (GTEx data) samples from
GEPIA database (here *P <0.01). B. Box plot representing the mRNA expression profiles
of PAF1C subunits (PAF1, LEO1, CTR9, CDC73, and SKI8), DDX3X, and PHF5A in high
tumor purity, low purity samples, and normal pancreas tissues (TCGA-PAAD) obtained
from GDC portal.
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Supplementary Figure 4: PHF5A is overexpressed in pancreatic CSCs. A. Box plot
representing the expression of PHF5A in 171 normal pancreatic tissues (GTEx) and 179
PC (TCGA-PAAD) cases from GEPIA database (here *P <0.01). B. Quantification of MFI
for PAF1 and PHF5A in SP and NSP cells from SW1990. Data representative of three
independent experiments. Error bars indicate mean ± S.E. C. Representative
immunofluorescence images depicting co-localization of PAF1 with PHF5A in distinct
cancer cells within human PC tissues (white arrows). Zoomed images of individual cells
showing co-localization are represented in the middle panel. Lower panel shows
expression of PAF1 and PHF5A in normal pancreas. D. Chromosome-wide distribution of
PAF1 and PHF5A peaks in SW1990 SP cells at a false discovery rate of less than 0.05.
E. Bar plots representing expression of Nanog in control versus PAF1 depleted and control
versus PHF5A depleted CSCs. Data representative of three independent experiments and
error bars indicate mean ± S.E. *P <0.05, **P <0.01, ***P <0.001.
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Supplementary Figure 5: DDX3 is a novel PAF1 interacting partner that is
overexpressed in pancreatic CSCs. A. Immunoprecipitation analysis with PAF1 from F9
cells followed by immunoblotting with PAF1 and DDX3. B. Box plot representing
expression of DDX3 in normal (171 cases) and human PC tissues (179 cases) obtained
from GEPIA database (*P <0.01). C. Immunofluorescence analysis of PAF1 and DDX3 in
human PC and normal pancreatic organoids (top panel), and in mouse KPC and normal
pancreatic organoids (lower panel). Data representative of two independent experiments.
D. Mean fluorescent intensity of PAF1 and DDX3 in SP and NSP cells from SW1990. Data
representative of two independent experiments (*P <0.05). E. Immunofluorescence
analysis of PAF1 and NANOG in human PC tissues and normal pancreas. Tissue
histology is represented on the left as Hematoxylin and Eosin stained images. F. KaplanMeier survival curve for overall survival of PC patients with high and low Nanog expression
extracted from GEPIA database.
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Supplementary Figure 6: DDX3 inhibitor RK-33 reduces colony formation ability of
pancreatic CSCs and induces apoptosis. A. Growth curve representing IC50 values for
RK-33 in SW1990 SP cells, Capan1 SP cells and 9-26 NP fibroblasts. IC50 values are:
SW1990 SP = 4.32 μM, Capan1 SP = 5.53 μM, and 9-26 NP = 9.23 μM. SEM values are:
SW1990 SP = 0.040, 0.027, 0.042, 0.038, 0.015, 0.022, 0.014, 0.016, 0.014; Capan1 SP
= 0.064, 0.036, 0.067, 0.039, 0.069, 0.017, 0.010, 0.010; and 9-26 NP = 0.060, 0.068,
0.077, 0.051, 0.117, 0.062, 0.017, 0.010. B. Immunoblotting analysis for DDX3, PAF1,
CD44v6, SOX9, and β-CATENIN with RK-33 treatment in SW1990 NSP and Capan1 NSP
cells for 48 h. β-ACTIN was used as a loading control. C. Graphical representation of total
colony area in a colony formation assay with control and RK-33 (5 µM)-treated SW1990
SP cells. Data representative of three independent experiments and error bars indicate
SEM vales. Cells were treated for 48 h and colonies were stained 15 days following
seeding. D. Representative images for morphology of SW1990 SP cells following
treatment with RK-33 (5 µM) for 48 h. E. Scatter plots demonstrating apoptotic cells
following 48 h treatment with RK-33 (5 µM) in SW1990 SP and 9-26 NP cells.
Quantification of percentage of late apoptotic (Annexin V and PI double positive) cells is
shown below. *P <0.05, **P <0.01, ***P <0.001. n.s. = non-significant.
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Supplementary Figure 7: PAF1 regulates array of stem cell genes. A. Heatmap of
differentially expressed metastasis-promoting genes in control and PAF1 depleted
SW1990 SP cells. B. Heatmap of differentially expressed relapse genes in control and
PAF1 depleted SW1990 SP cells. C. Heatmap representing differential fold expression of
genes downregulated upon PAF1 depletion using PCR array (left panel) and mean
promoter occupancy of PAF1 on these gene promoters (right column).
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Supplementary Table 1: Primer sequences for binding sites (B.S.) on Nanog
promoter

Gene Name

(Forward and Reverse primers)

B.S.1

F: CATTTGGCATGTGTGTCAACTC
R: TTCAAGTGATAGGATTTGGATAGGG
F: GGATTTGGTCAGCTCCTTTACT
R: GAACCAGAACGACTCCATCTTC
F: GTCTCAGCCTCCCTAGTAGAT
R: CACCTGTAATCCCAGCACTT
F: CTGCCTGAAGCATGATGTACTA
R: CTCCCACACAAGCTGACTTT
F: CATAATCGGGATTTGCTAAGAGTTT
R: TGTGGGTGTGTGTGTTTCT
F: TGCCTTGGCTTCATGCTATAA
R: CTGAGGTTATTGAAATTCTCATTAGGG
F: GCCTCCCAATTTACTGGGATTA
R: CGAGCAACAGAACCTGAAGA
F: TGAGACTGGTAGACGGGATTA
R: GAAATAGGACCTCCAGAAGGAAA

B.S.2
B.S.3
B.S.4
B.S.5
B.S.6
B.S.7
B.S.8
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Amplicon
Size (bp)
92
181
174
180
211
168
178
222

Supplementary Table 2: Primers used in q-RTPCR

Gene Name
PAF1/PD2
Sox9
CD44v6
β-Catenin
ALDH1A3
CTR9
LEO1
CDC73
β-actin
Nanog

(Forward and Reverse primers)
F: CTCACAGCATTACAGCAAACC
R: GTCTCTTCTACAGGCAGGAAAT
F: GAGCCGGATCTGAAGAGGGA
R: GCTTGACGTGTGGCTTGTTC
F:CCAGGCAACTCCTAGTAGTACAACG
R: CGAATGGGAGTCTTCTTTGGGT
F: AAAATGGCAGTGCGTTTAG
R: TTTGAAGGCAGTCTGTCGTA
F: ATCAACTGCTACAACGCCCT
R: TATTCGGCCAAAGCGTATTC
F: AAATTCTCGGCTCTCTCTATGC
R: GGGATACTGTTCTGTGACCTTC
F: AGTGTAGAGCCCAGACCTT
R: CCTTCTTCATCTCGGCGTATC
F: GCCTTCCATCTGAAGTATGATGA
R: TGTACCTGTCCAATGTTTCCC
F: GGACATCCGCAAAGACCTGTA
R: GCTCAGGAGGAGCAATGATCT
F: CCTGTGATTTGTGGGCCTG
R: GACAGTCTCCGTGTGAGGCAT
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Amplicon Size(bp)
231
151
112
100
98
92
143
142
143
78

Supplementary Table 3: List of antibodies used in Western blot
ANTIBODIES

SOURCE

IDENTIFIER AND DILUTION

List of primary antibodies used in Western blot
Non phospho βCATENIN

Cell Signaling Technology

Cat# CST-19807P (Rb) (1:1000)

ALDH1

Santa Cruz Biotechnology

Cat# sc-374149 (Ms) (1:1000)

CD44

Cell Signaling Technology

Cat# CST-5640S (Ms) (1:1000)

OCT3/4

Santa Cruz Biotechnology

Cat# sc-5279 (Ms) (1:500)

PAF1/PD2

Bethyl Laboratories

Cat# Bethyl-A300-173A (Rb)
(1:5000)

CD44v6

Thermo Fisher Scientific

Cat# BMS125 (Ms) (1:1000)

CD24

Santa Cruz Biotechnology

Cat# sc-19585 (Ms) (1:1000)

ESA (EpCAM)

Cell Signaling Technology

Cat# CST 2626 (Rb) (1:1000)

CD133

Cell Signaling Technology

Cat# CST-5860 (Rb) (1:1000)

DDX3

Abcam

Cat# ab235940 (Rb) (1:1000)

LEO1

Bethyl Laboratories

Cat# A300-174A (Rb) (1:1000)

CTR9

Bethyl Laboratories

Cat# A301-395A-1 (Rb) (1:1000)

CDC73

Bethyl Laboratories

Cat# A300-170A (Rb) (1:1000)

β-Actin

Santa Cruz Biotechnology

Cat# sc-47778 (Ms) (1:2000)

PHF5A

Proteintech

Cat# 15554-1-AP (Rb) (1:500)

SOX2

Santa Cruz Biotechnology

Cat# sc-20088 (Rb) (1:500)

SOX9

Abcam

Cat# ab26414 (Rb) (1:1000)

NANOG

Thermo Fisher Scientific

Cat# PA1-097 (Rb) (1:1000)

List of secondary antibodies used in Western blot
Goat anti-Rb IgG
HRP

Invitrogen

Cat# 31460 (1:3000 to 1:5000)

Goat anti-Ms IgG
HRP

Invitrogen

Cat# 31430 (1:3000 to 1:5000)
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Supplementary Table 4: List of antibodies used in immunofluorescence and
immunohistochemistry
ANTIBODIES

SOURCE

IDENTIFIER/DILUTION

List of primary antibodies used in Immunofluorescence and Immunohistochemistry
SOX9

Abcam

Cat# ab182579 (Rb) (1:300)

DDX3

Abcam

Cat# ab235940 (Rb) (1:300)

CD44v6

Thermo Fisher Scientific

Cat# BMS125 (Ms) (1:300)

PAF1/PD2 rabbit Ab

Abcam

Cat# ab20662 (Rb)(1:250)

PAF1/PD2 mouse mAb

Our lab

N/A (Ms) (1:100)

Nanog

Santa Cruz

Cat# sc-293121 (Ms) (1:150)

Biotechnology
PHF5A

Proteintech

Cat# 15554-1-AP (Rb)(1:200)

Non phospho β-CATENIN

Cell Signaling

Cat# CST-19807P (Rb)

Technology

(1:300)

ALDH1/2

Santa Cruz

Cat# sc-374149 (Ms) (1:300)

Ki67

Cell Signaling

Cat # 9449 (Ms) (1:300)

Technology
List of secondary antibodies used in Immunofluorescence
Alexa Fluor 568 goat anti-

Life Technologies

Cat# A11004 (1:300)

Alexa Fluor 568 goat anti-rabbit Life Technologies

Cat# A11011 (1:300)

mouse IgG
IgG
Alexa Fluor 488 goat anti-

Life Technologies

Cat# A11001 (1:300)

Alexa Fluor 488 goat anti-rabbit Life Technologies

Cat# A11008 (1:300)

mouse IgG
IgG
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Supplementary Table 5: List of antibodies used in chromatin immunoprecipitation
and flow cytometry
List of antibodies used in Immunoprecipitation assay and ChIP assay
PAF1/PD2

Abcam

Cat# ab20662 (Rb)
(3µg/900µg protein)

PHF5A

Proteintech Group

Cat# 15554-1-AP (Rb)

ChromPure IgG

Jackson

Cat# 011-000-003 (Rb)

Immunoresearch

(3µg/900µg protein)

Laboratories
DDX3

Abcam

Cat# ab235940 (Rb)
(3µg/900µg protein)

List of antibody used in Flow cytometry
CD44 APC Human

Miltenyi Biotech
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Cat# 130-098-110
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CHAPTER 5

Understanding the role of Paf1 in
pancreatic homeostasis and progression
of pancreatic ductal adenocarcinoma:
Generation of KrasG12D; Trp53R172H/+;
Pdx1-Cre; Paf1fl/fl (KPCP) mice
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Synopsis
Paf1, a component of RNA-polymerase II-associated factor 1 has been reported to be
overexpressed in pancreatic cancer and cancer stem cells, but its involvement in pancreas
homeostasis and PDAC progression is not well defined. We aimed to address this
question by generating Paf1 pancreas-specific knockout mice and KrasG12D; Trp53R172H/+;
Pdx1-Cre; Paf1fl/fl (KPCP) mice that have a pancreas-specific knockout of Paf1 along with
Kras and p53 mutations. Paf1 knockout (Paf1-/-) mice display significantly decreased
pancreas weight compared to control floxed mice. Histologically, Paf1-/- mice showed loss
of acinar parenchyma and naked ducts up to 5 months of age, whereas older mice did not
show this phenotype. RNA-seq analysis indicated the downregulation of pathways
involved in system development of the pancreas, suggesting a possible role for Paf1 in
acinar lineage differentiation and cell survival. To elucidate the in vivo role of Paf1 in PDAC
progression, the KPCP mice were monitored for tumor progression at several time points
and were compared to KPC mice. Our results indicate that knockout of Paf1 decreases
PDAC latency with the appearance of tumors as early as 10 weeks. The majority of 10
and 15 weeks KPCP mice harbor PDAC, whereas pancreatic intraepithelial neoplasia
lesions (PanIN) start appearing by 5 weeks. KPCP mice showed a significant decrease in
overall survival rate as compared to KPC mice. There was a remarkable increase of
Vimentin, an EMT marker in KPCP mice, which could explain faster tumor progression
and metastasis in these mice. Overall, our findings suggest a novel role for Paf1 in acinar
differentiation and indicate that genomic depletion of Paf1 accelerated PDAC progression.
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Background and rationale
Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second mostcommon cause of cancer-related deaths by 2030 [1]. It has the worst prognosis of all major
cancers due to a lack of effective diagnostic approaches and systemic therapeutic
modalities. A comprehensive understanding of the progression of this disease and the
initial events that trigger tumor development is still lacking [2]. About 90% of pancreatic
cancer (PC) is ductal adenocarcinoma and pancreatic intraepithelial neoplasias (PanINs)
are the most important type of PDAC precursors. Tumorigenesis is believed to be a
stepwise progression from low-grade PanINs to high-grade PanINs and then to invasive
adenocarcinoma. However, emerging studies define PDAC origin from the acinar cells
rather than the ductal cells. This could be possible due to the trans-differentiation of acinar
cells into ductal morphology. This concept, known as acinar-to-ductal metaplasia (ADM)
is characterized by a class of transitional cells that are predisposed to neoplastic
transformation [3, 4]. On the other hand, cancer stem cells (CSCs) are a small subset of
tumor cells involved in the aggressiveness and progression of the disease [5-10]. Recent
observations in genetically engineered mouse models suggest that ADM, precedes PanIN
formation and PDAC tumorigenesis and that acinar, centroacinar cells, and stem cells can
give rise to ADM and thereafter PDAC [11]. Therefore, there is an immediate need to
identify those factors that promote the trans-differentiation process and contribute to tumor
induction, as well as those required for CSC maintenance that contributes to tumor
maintenance and aggressiveness. This knowledge may prove beneficial for the
establishment of early biomarkers and disease management through a more
comprehensive understanding of cancer initiation and progression.
Detailed genomic analysis has engendered a genetic model of tumorigenic progression
with activating mutations in Kirsten rat sarcoma viral oncogene (KRAS) as the major
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initiator followed by loss-of-function mutations in tumor suppressors such as TP53,
CDKN2A, and SMAD4 [12, 13]. Furthermore, oncogenic Kras expression specifically
targeted to pancreatic progenitor cells is sufficient for the spontaneous formation of PanIN
lesions in mouse models. The most well-studied models of PDAC progression are the KC
(LSL-KrasG12D/+; Pdx1-Cre) and KPC (LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx1-Cre)
models. While the KC mice show a full spectrum of PanINs, they progress to PDAC at
approximately 50 weeks and rarely exhibit metastasis. The KPC model, with physiologic
expression of Trp53R172H and concomitant endogenous KrasG12D expression, present
metastatic PDAC with a 100% penetrance at 20-25 weeks. The KPC model recapitulates
the principal clinical and histopathological features of the cognate human disease
including metastases to lungs, liver, and hemorrhagic ascites [14].
Paf1 is the core component of RNA Polymerase II-associated factor 1 complex (PAF1C)
that mediates transcription elongation, mRNA processing and export. Ectopic
overexpression of Paf1 in NIH3T3 cells showed transforming activity [15]. Expression of
Paf1 has been reported to vary spatially and temporally based on cell cycle progression.
Paf1 expression increased in S-phase, reached a maximum level of expression in G2, and
was degraded during mitosis. The Paf1 variation of expression/localization during the
progression of the cell-cycle is similar to the differential expression pattern of the cyclin
proteins, more specifically, cyclin B1 [16]. Prior studies have shown that Paf1 plays a role
in mediating ADM as it is specifically expressed in metaplastic ducts along with acinar
marker amylase and ductal marker CK19 [17]. In normal mice, cerulein-mediated
inflammation that induces ADM-like histology caused a decrease in Paf1 expression,
which was later restored upon recovery of the pancreatic parenchyma. However, in KC
(LSL-KrasG12D/+; Pdx1-Cre mice), Paf1 mRNA level exhibited a continual decrease with
progressive dysplasia and subsequent neoplastic transformation. Further, knockdown of
Paf1 in pancreatic acinar cells resulted in the abrogation of Amylase, Elastase, and Lipase
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(acinar markers) mRNA levels with simultaneous increase in CK19 and CAII (ductal
markers) transcripts. In another study, ectopic overexpression of Paf1 in PDAC cells led
to enhanced tumorigenesis and metastasis in xenograft studies. These studies suggest
that Paf1 plays a role in promoting pancreatic tumorigenesis. Since the whole-body
knockout of Paf1 is embryonic lethal, we used a CRISPR-based conditional knockout
mouse model for the pancreas-specific deletion of Paf1. Based on aforementioned
literature, we hypothesized that ‘pancreas-specific depletion of Paf1 has a profound effect
on PDAC progression and metastasis’.

Results
A. Generation of Paf1 conditional knockout mouse model
We used CRISPR/Cas9-based gene-targeting strategy to insert loxP sites flanking exon
4 of the mouse Paf1 gene. Genotyping primers were designed to identify the 5’ loxP site
and 3’ loxP site (Table 1). Using this strategy 5’ homozygous floxed mice (Paf1fl/fl) yielded
a single mutant band of 166 bp, heterozygous mice gave two bands of 166 bp and 126
bp, whereas the wild type mice gave a single band of 126 bp when resolved on 2%
agarose gel. Similarly, the expected wildtype type and mutant bands for 3’ loxP sites were
397 bp and 431 bp, respectively (Figure 1). Crossing these floxed mice (Paf1fl/fl) with
Pdx1-Cre mice led to deletion of exon 4 and loss of Paf1 expression. Paf1 knockout was
validated in mouse embryonic fibroblasts (MEFs) generated from Paf1 homozygous (Paf1), heterozygous (Paf1fl/+), and wild type (Paf1fl/fl) embryos following adenoviral Cre
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transduction (Figure 2A). Using immunoblotting, we confirmed the complete knockout of
Paf1 in homozygous MEF line, decrease in expression in heterozygous line and no
significant difference in wild type line (Figure 2B).
B. Paf1 knockout resulted in severe loss of pancreatic parenchyma
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Gross morphological examination of the pancreas from Paf1 homozygous-deleted (Paf1) mice revealed a drastic decrease in the overall weight of pancreatic tissue compared to

/-

homozygous-floxed (Paf1fl/fl) mice (Figure 3A and B). The exocrine pancreas is
composed of lobular units of acini that accounts for bulk of the pancreatic parenchyma
and discharge digestive enzymes into progressively larger ducts. Ducts merge into the
main pancreatic duct that carries the enzymes to the duodenum. The islets of Langerhans,
which constitute 1-2% of the adult pancreatic mass, represent the endocrine compartment
of the pancreas. Histological analyses using H and E staining indicated that loss of Paf1
resulted in a significant loss of acinar compartment with the appearance of peri-ductal
sclerosis and ‘naked duct-like’ morphology, along with associated immune infiltration
(Figure 4A). Of interest, the endocrine compartment was not affected by Paf1 deletion.
There was a progressive loss of acinar parenchyma with age up to 5-month of age (Figure
4B). However, heterozygous deletion of Paf1 affected neither the morphology nor the
histology of the pancreas (Figure 5). To validate the further the specific deletion of Paf1
from the pancreas, we collected pancreas, spleen, liver, and kidney from Paf1-/- and Paf1fl/fl
mice and performed immunoblotting for Paf1 expression in pancreas and other organs.
We observed complete loss of Paf1 from pancreas of Paf1-/- mice and not from spleen,
liver or kidney (Figure 6A). Additionally, we performed confocal microscopy to confirm the
loss of expression of Paf1 from acinar compartment in Paf1-/- mice compared to Paf1fl/fl
mice (Figure 6B). Similarly, nuclear expression of Paf1 was decreased in left-over acini
from Paf1-/- mice compared with Paf1fl/fl as seen by immunohistochemistry (Figure 6C).
The loss of pancreatic parenchyma in Paf1-/- mice compared with Paf1fl/fl mice was seen
up to 5-month-old mice. However, in older animals at 7-month, 9-month, and 12-month
time points, we did not observe any significant variations in pancreas weight between
Paf1-/- and Paf1fl/fl mice (Figure 7). Surprisingly, there was no significant difference in
overall body weight of Paf1-/- and Paf1fl/fl mice at the time points observed, including 1-
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month, 2-month, 3-month, 4-month, 5-month, 7-month, 9-month, and 12-month of age
(Figure 7).
C. Paf1 depletion affects several key transcripts that play a role in system
development
To gain mechanistic insights into Paf1-mediated acinar maintenance, we aimed to
examine global transcripts regulated by Paf1. RNA-sequencing analyses of the pancreas
from homozygous Paf1-deleted and foxed mice revealed pathways prevalent in system
development and acinar cell survival. Some of these transcripts downregulated following
Paf1 loss include Notch2 (cell fate and differentiation), Tbx19 (regulation of developmental
processes), Fgf7 (proliferation of pancreatic epithelial cells), Foxo6 (cell fate decisions),
Atf-3 (glucose and insulin homeostasis), Klf7 (cellular differentiation and insulin secretion)
(Figure 8). Based on analyses of candidate players identified via RNA-seq and other
histochemical analyses, we will be investigating the mechanism for the role of Paf1 in
acinar lineage differentiation and regeneration. Next, we sought to determine the in vivo
role of Paf1 in PDAC progression through generation of KPCP mouse model as detailed
in the next section.
D. Development of KPCP mouse model
Previous studies have described that genomic instability conferred by endogenous
expression of Trp53R172H and KrasG12D in the mouse pancreas leads to spontaneous
development of pancreatic ductal adenocarcinoma [14]. Point mutations in Kras (G12D)
and Trp53 (R172H) are switched on within the mouse pancreas by breeding LSLKrasG12D/+; LSL-Trp53R172H/+ mice to Pdx1-Cre mice. Therefore, in the KPC mice, activation
of both the KrasG12D and the Trp53R172H alleles occurs in tissue progenitor cells of the
developing mouse pancreas through interbreeding with Pdx-1-Cre transgenic animals.
LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre mice have a median survival of approximately
5 months. The KPC animals succumb to PDAC much earlier than KC animals that have a

145

longer latency to develop PDAC after manifesting pre-invasive disease. Similar to clinical
presentations of human PDAC, the majority of the KPC animals develop cachexia,
abdominal distention, and hemorrhagic ascites. Furthermore, metastasis to the liver,
lungs, diaphragm, and adrenals is frequently encountered. To explore the role of Paf1 in
pancreatic cancer, the KPC (KrasG12D; Trp53R172H/+; Pdx1-Cre) mice were bred with Paf1
floxed (Paf1fl/fl) mice that resulted in KPCP mice (KrasG12D; Trp53R172H/+; Pdx1-Cre; Paf1fl/fl).
The breeding strategy for the generation of KPCP mice has been outlined in Figure 9.
E. Deletion of Paf1 leads to faster PDAC progression
We noted that knockout of Paf1 in the background of Kras and Trp53 mutations
accelerated the development of PDAC (Figure 10A). Low-grade PanIN1 were observed
as early as 3 weeks (Figure 10B). At 5 weeks, 60% of KPCP mice displayed high-grade
PanIN2 and PanIN3 lesions, which increased to 67% by 10 weeks (Figure 11). The
development of these high-grade lesions was very rapid as compared to KPC mice, which
usually develops these high-grade lesions by 10 weeks. At 10 and 15 weeks, KPCP mice
showed a greater percentage of high-grade PanIN lesions than KPC mice with statistical
significance (Figure 11). Since these high-grade benign lesions, also known as
Carcinoma in situ (CIS), eventually leads to PDAC development, KPCP was evaluated at
different time points starting from 3 weeks to 20 weeks to monitor PDAC progression
(Figure 12). Fully blown pancreatic tumors were apparent as early as 10 weeks (33%)
and at 10 and 15 weeks, the tumor incidence in KPCP mice was higher than that of KPC
mice (Figure 12). Heterozygous deletion of Paf1 showed tumor incidence intermediate
between KPCP and KPC mice. Histopathologic analysis of KPCP tumors revealed poorly
differentiated/undifferentiated morphology; however, a vast majority of KPC animals
developed well to moderately differentiated tumors.
F. Loss of Paf1 significantly decreased survival of Paf1 knockout and KPCP mice
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First, we compared the survival of Paf1-/- mice with that of control Paf1fl/fl mice to determine
whether loss of acinar compartment had an effect on survival. We did not observe any
statistically significant difference in survival of Paf1 knockout and homozygous floxed
control mice (data not shown). We noted that PDAC progression in KPCP mice was very
rapid as compared to KPC mice, which usually develops PanIN lesions by 10 weeks and
full-blown tumors by 20-25 weeks. We also evaluated the effect of knockout of Paf1 in
KPC background on overall survival as it induced faster disease progression. We used 11
animals for survival studies in each group which are: KPCP (KrasG12D/+; Trp53R172H/+; Pdx1Cre; Paf1fl/fl); het KPC (KrasG12D/+; Trp53R172H/+; Pdx1-Cre; Paf1fl/+) and KPC (KrasG12D/+;
Trp53R172H/+; Pdx1-Cre). The median survival of KPC control littermates was around 200
days (28.6 weeks), whereas KPCP mice have a dramatically shortened mean survival of
104 days (14.8 weeks) (Figure 13). Likewise, the survival of heterozygous KPC was
intermediate between that of homozygous KPCP and KPC mice at 134 days (19.2 weeks).
Taken together, these findings suggest that knockout of Paf1 along with Kras and p53
mutations significantly augments PDAC initiation and impacts survival.
G. Loss of Paf1 enhances expression of mesenchymal markers
Cell line derived from KPCP mice showed a significantly higher expression of
mesenchymal markers Vimentin and Snail compared to KPC cell line. Also, KPCP cell line
showed reduced expression of epithelial marker ZO-1 compared to KPC cell line (Figure
14). Similarly, immunohistochemical analyses suggested a significantly higher expression
of Vimentin in KPCP tissues compared to KPC tissues (Figure 14). This suggests that the
KPCP tumor cells may show a greater propensity for epithelial to mesenchymal transition,
which is considered to be an important step in the metastatic cascade. The significance
of higher expression of mesenchymal markers by KPCP tumors compared to KPC tumors
warrants further investigation.
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Discussion
PDAC remains a challenging disease owing to late diagnosis and metastatic spread prior
to diagnosis. Although human PDAC genome sequencing has identified recurrent
mutations in Kras and many tumor suppressor genes, the impact of these alterations in
the initiation and early stages of human PDAC development remains poorly understood
at the molecular level. While PDAC was originally thought to arise from ductal cells due to
its histological appearance, evidence from mouse models suggests that acinar cells can
give rise to PDAC through a regenerative, transdifferentiation process known as ADM.
Further, recent studies investigating mechanisms of ADM indicated that acinar cells
display a greater degree of plasticity compared to centroacinar and ductal cells. However,
it is unclear whether all acinar cells display the same ability to dedifferentiate during injuryinduced cellular reprogramming, or there is a specific subset with greater plasticity [18,
19]. Pancreatic regeneration following the injury can be explained by the existence of
quiescent/reserve progenitors or through dedifferentiation of acinar cells to act as
facultative progenitor cells. Support for the former notion came from a recent study that
showed that Dclk1 marks a rare population of long-lived, quiescent acinar cells that are
necessary for pancreatic regeneration following injury and chronic inflammation and can
serve as cancer-initiating cells under the influence of mutant Kas [18]. Another study
demonstrated that Krüppel-like factor 4 (KLF4) transcription factor, which was initially
identified as an important regulator of cell fate decisions, is critical for lineage
differentiation in the ADM process, and plays a cardinal role in the progression of PC [20].
A subsequent study revealed YAP1 and TAZ control PC initiation through the ADM
process by up-regulating JAK-STAT3 signaling [21]. All of these studies indicate a
neoplastic transition of acinar cells toward a ductal phenotype through intermediate
structures representing precursor lesions, which ultimately progress to invasive
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adenocarcinoma [5, 6, 8-10]. Literature suggests that upon pancreatic inflammation or
damage, an expanded “stem cell”-like compartment is seen that could represent a
subpopulation of cells susceptible to oncogenic transformation upon somatic mutation of
key proto-oncogenes and tumor suppressor genes [5, 6, 8-10, 22]. Since we found the
role of Paf1 in the maintenance of oncogenesis and pancreatic CSCs, we sought to
delineate its role in ADM and pancreatic tumorigenesis.
Our study is a maiden attempt to understand the role of a Polymerase-associated
protein, Paf1, in pancreatic homeostasis and PDAC progression. We found that
conditional deletion of Paf1 from mouse pancreas caused a 50% reduction in the pancreas
weight and a significant loss of acinar parenchyma in young mice up to 5-month of age.
We observed peri-ductal sclerosis and the appearance of naked ducts in Paf1
homozygous knockout mice. To our surprise, the acinar compartment is restored in older
mice from 9-month to 12-month of age, indicating the role for Paf1 in acinar maintenance
and regeneration. Similarly, there is no significant difference in the weight of the pancreas
between Paf1-depleted and control mice at 9-month and 12-month age. On evaluation of
global changes in pancreas from Paf1-depleted and Paf1 homozygous floxed mice though
RNA-sequencing, we found significant enrichment of pathways involved in system
development and morphogenesis among the downregulated genes. Members of the
Notch signaling pathway, including Notch2 and Fgf7, were downregulated. Numerous
reports have demonstrated the pivotal role of Notch signaling in pancreatic specification,
cell proliferation, differentiation, and plasticity [23, 24]. Of importance, levels of Notch
pathway mediators regulate the quiescence, self-renewal, and differentiation of pancreatic
progenitors’ cells during pancreas development. Given the important roles of Notch and
Fgf signaling in pancreas regeneration and homeostasis, the downregulation of these
mediators in Paf1 knockout mice has partially explained the drastic phenotype observed.
However, delineation of a clear mechanism for Paf1 regulated pancreas homeostasis
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warrants further investigation. It will be instructive to investigate the most differentially
regulated transcripts at earlier time points such as 1 week and 4 weeks following birth,
which would be representative of most acute phases of acinar damage. Conversely,
looking at the differential transcript landscape at later time points such as in 7-month and
9-month old mice will help delineate the role of Paf1 in acinar regeneration and recovery
from damage. A more comprehensive understanding of the role of Paf1 in the
maintenance of acinar identity and in facilitating acinar regeneration will emerge from the
systematic comparison of differentially expressed transcripts at different times following
acinar damage.
To understand the role of Paf1 in PDAC progression, we generated the KPCP
model that had Paf1 deletion in the background of endogenous expression of mutant Kras
and p53. Although we expected delayed progression owing to the role of Paf1 in the
maintenance of pancreatic CSCs, we found a significantly faster disease progression in
KPCP mice compared with age matched KPC mice. High-grade PanINs were observed
as early as 5 weeks and were significantly more frequent at 10 and 15 weeks in KPCP
mice than KPC controls. Further, KPCP mice showed greater tumor incidence than KPC
mice at 5, 10 and 15 weeks. Perhaps, the most striking observation was that majority of
KPCP mice died before reaching 16-17 weeks of age. These findings can be reconciled
considering that deletion of Paf1 alone results in a severe loss of acinar parenchyma,
which represents a vulnerability in which genetic and environmental factors can act to
induce neoplastic transformation. There is evidence of acinar regeneration from studies
with experimental models of acute pancreatitis where treatment with a cholecystokinin
analogue cerulein stimulates the premature release of trypsin in the pancreas and causes
extensive acinar damage [25]. This cerulein-induced acinar damage is transient, and the
acinar compartment undergoes regeneration to repair the damage in the absence of
subsequent inflammation or oncogenic insults. During such an inflammatory insult, the
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acini can either undergo apoptosis or transdifferentiate to ductal cells [26]. Acini are
proposed to undergo regeneration via two distinct modes in experimental models of
pancreatitis (Figure 15). In the classical regeneration mode, new acini are generated from
the proliferation of pre-existing acini [27, 28]. The alternative regeneration mode posits
that the degranulated and duct-like acinar cells re-differentiate back to normal acinar state
[26]. However, during persistent inflammation or with KrasG12D mutation, acinar
regeneration is impaired, and cells undergoing ADM give rise to PanINs that ultimately
progress to PDAC with subsequent mutations [26, 28]. Considering that Paf1 loss results
in impairment of acinar maintenance and an increase in ADM, we propose that such a
dedifferentiated state of acinar cells makes the mouse pancreas more susceptible to
subsequent insults (Kras and p53 mutations in this case) (Figure 15).
PDAC is a very complex disease with more than 50 genetic alterations present
within each tumor [29]. Previously, a transcription factor Klf4 has been suggested to play
stage-dependent functions in PDAC pathogenesis. Based on findings by Wei et al. using
Klf4 loss and gain of function in the background of mutant Kras, KLF4 has a
protumorigenic function in PDA initiation but a tumor-suppressive function in developed
PDAC. It is possible that Paf1 plays a stage-dependent role during PDAC progression,
wherein it is tumor-suppressive in preneoplastic PanINs and tumor-promoting in fully
developed PDAC. This notion is partly corroborated by our findings of higher incidence of
PanINs and faster PDAC progression due to the depletion of Paf1 from pancreatic
progenitors since birth using Pdx1-Cre. Likewise, Paf1 loss from mouse acinar cells
decreased acinar markers with a concomitant increase in ductal markers and promoted
cerulein-induced ADM [17]. On the flip side, Paf1 is also required for the maintenance of
cancer stem cells. We and others have demonstrated that the proportions of CSCs
increase significantly with tumor progression [30]. It is likely that the pro-tumorigenic
function of Paf1 is more significant at later PDAC stages when it is required for the
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maintenance of tumor stem cells as opposed to acinar regeneration. Further, Paf1 also
regulates cell cycle progression by controlling the expression of cyclins such as A1, A2,
D1, E1, B1, and Cdk1. Paf1 has been shown to regulate the G2/M transition via cyclin B1
expression and delay entry into the S phase by limiting DNA Polymerase α functionality
during DNA replication [16]. Additionally, Paf1 plays a role in lineage specification of
embryonic stem cells [31]. Therefore, those fundamental functions of Paf1 in the regulation
of cell cycle and differentiation may facilitate different biological outcomes, depending
upon cell lineage and functional status. The detailed molecular basis for such stagedependent or context-dependent tumor-promoting or tumor-suppressor functions of Paf1
in PDAC warrants further investigations. To delineate the stage-specific functions of Paf1
in tumor initiation and maintenance, we propose to cross Paf1 floxed mice with KP
(KrasG12D/+; Trp53R172H/+) mice and thereafter cross the resulting progeny (KrasG12D/+;
Trp53R172H/+; Paf1fl/fl) with Ptf1a CreER mice, entailing tamoxifen-inducible Paf1 deletion.
Tamoxifen administration at 15-20 weeks would entail Paf1 depletion at later stages of
PDAC pathogenesis. Delayed PDAC progression or absence of aggressive tumors, in this
case, would suggest that Paf1 is required for tumor maintenance. Similarly, more
aggressive and faster PDAC progression following inducible Paf1 overexpression at 1520 weeks would reiterate that Paf1 plays a cardinal role in tumor maintenance (Figure
16). Conversely, an enhanced PDAC progression upon Paf1 depletion in adult mice at
initial stages of PDAC pathogenesis using an inducible Cre would suggest a tumorsuppressive role for Paf1. Altogether, our studies demonstrated a previously unknown role
for Paf1 in acinar lineage differentiation and acinar maintenance and elucidated the in vivo
role of Paf1 in PDAC pathogenesis.
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Figure 1: Representative 2% agarose-gel electrophoresis images depicting
genotyping results for Paf1. Top panel indicates the bands obtained for 5’ arm
genotyping and the lower panel shows the band sizes for 3’ arm. The expected band sized
for mutant and wild type alleles are indicated.
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Figure 2: Analysis of Paf1 expression in MEFs generated from conditional
CRISPR/Cas9 knockout mice.
A. Schematic representation of breeding strategy used for creation of MEF cell lines from
embryos with wild type, Paf1 homozygous or heterozygous floxed alleles. MEF cell lines
were transduced with adenoviral Cre recombinase to induce Paf1 knockout (line 1) or Paf1
knockdown (line 2).
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Figure 3: Morphology of Paf1 conditional CRISPR/Cas9 knockout mice.
A. Representative images indicating the gross morphology of pancreas in Paf1
homozygous-deleted and homozygous floxed (control) mice. Pancreas looked healthy in
control mice whereas pancreas from homozygous Paf1-depleted mice showed
inflammation based on gross morphological observations during necropsy. B. Graphical
representation of pancreas weight from Paf1 homozygous knockout (Paf1-/-) and control
(Paf1fl/fl) mice.
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Figure 4: Histological variations in Paf1 conditional CRISPR/Cas9 knockout mice.
A. Representative H and E images of mouse pancreas from Paf1-/- and Paf1fl/fl mice at 3month age, indicating immune infiltration, peri-ductal sclerosis and acinar cell loss. B.
Representative images of whole pancreas from Paf1-/- and Paf1fl/fl mice at 1-month, 3month, and 5-month time point, indicating progressive loss of acinar compartment.
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Figure 5: Histological variations in homozygous and heterozygous Paf1-deleted
pancreas.
Representative H and E images from Paf1fl/+ and Paf1fl/fl mice at 3 and 5-month age,
indicating no gross difference in histology. Pancreas from heterozygous Paf1-deleted
(Paf1fl/+) and control homozygous floxed (Paf1fl/fl) mice showed normal islets, acinar and
ductal structures.
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Figure 6: Validation of loss of Paf1 from Paf1 CRISPR/Cas9 knockout mice.
A. Immunoblotting depicting expression of Paf1 in pancreas, spleen, liver, and kidney
isolated from Paf1-/- and Paf1fl/fl mice. B. Confocal microscopic images indicating loss of
Paf1 expression from acini of Paf1-/- mice compared with Paf1fl/fl mice. C. Composite score
for immunohistochemical analysis of Paf1 expression in pancreata obtained from 1, 2, 3,
4 and 5-month old Paf1-/- and Paf1fl/fl mice.
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Figure 7: Body weight and pancreas weight of control and homozygous Paf1
knockout mice.
A. There was no difference in body weight of Paf1 knockout mice and control homozygous
floxed mice at 1, 2, 3, 4, and 5 months of age. B. The pancreas weight of Paf1 knockout
mice at each time point was significantly lower than that of control floxed mice. C. The
body weight of Paf1 knockout mice and control homozygous floxed mice did not differ
significantly in older mice at 7, 9, and 11 month time points. D. The pancreas weight of
Paf1 knockout mice at later time points was not different from that of control floxed mice.
The mouse body weight was recorded just before necropsy. The weight of complete
pancreas was measured. Each time point consists of at least four animals or more.
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Figure 8: Pathways downregulated in Paf1 knockout mice.
A. Expression of Paf1 relative to Actin was measured in RNA isolated from Paf1
homozygous floxed and Paf1-deleted mice by qRT-PCR. RNA was isolated from animals
at 3-months of age. Quantification of fold change of Paf1 expression relative to actin is
shown. Data represents 3 independent experiments with 3 biological replicates. B. Gene
Ontology enrichment analysis of genes significantly downregulated in Paf1 knockout mice
enriched system development and cell morphogenesis-related pathways. Expression of
individual genes belonging to these pathways are depicted in the heatmaps. Each column
represents RNA obtained from pancreas of a single animal. Three biological replicates
were used for Paf1 knockout and homozygous floxed control each.
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Figure 9: Schematic representation of the breeding strategy for the development
of KrasG12D; Trp53R172H/+; Pdx1-Cre; Paf1fl/fl (KPCP) mouse model to investigate the
role of Paf1 in PDAC progression.
KrasG12D; Pdx1-Cre and LSLTrp53R172H/+ were crossed with Paf1fl/fl mice separately to
obtain the F1 progeny with KrasG12D; Paf1+/fl; Pdx1-Cre and LSLTrp53R172H/+; Paf1+/fl
genotype. Intercrossing of F1 progeny resulted in KrasG12D; Trp53R172H/+; Pdx1-Cre; Paf1fl/fl
(KPCP) mice. Following birth, the F2 progeny was then euthanized at 3, 5, 10, 15 and 20
weeks of age to analyze pancreatic cancer progression in the absence of Paf1.
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Figure 10: Loss of Paf1 results in faster PDAC progression.
A. Gross appearance of pancreatic tumors in KPC and KPCP mice. Large pancreatic
tumor was seen for KPCP mice at around 15 weeks as compared to 30 weeks KPC mice
that formed with a much small pancreatic tumor. Splenomegaly was observed in 15 weeks
KPCP mice. B. Representative histological pictures of the pancreas from KPC and KPCP
mice at 5, 10, 15 and 20 weeks. (n=5 for KPC and KPCP mice). H and E stained pictures
reveal the appearance of neoplastic lesions at around 3-5 weeks in KPCP mice as
compared to KPC mice, which has a normal pancreas. Tumors were seen in 10, 15 and
20-weeks KPCP mice. However, KPC mice showed late tumor development at around 20
weeks. All the pictures were taken at 20X magnification.
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Figure 11: Loss of Paf1 accelerates PanIN development.
Both low grade (PanIN1A and Pan1B) and high grade (PanIN2 and PanIN3) were more
frequent in KPCP mice than KPC mice. At 5 weeks, there was a trend towards greater
percentage of high grade PanINs in KPCP compared with age matched KPC animals. At
10 and 15 weeks, the percentage of high grade PanINs observed in KPCP mice was
significantly higher than that of KPC mice. A trend towards higher percentage of normal
acini in KPC versus KPCP was also observed, however, it was not statistically significant.
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Figure 12: Higher tumor incidence and early tumor development in KPCP and
heterozygous Paf1-depleted KPC mice compared with control KPC mice.
A. An increased percentage of tumor-bearing animals was observed in KPCP cohort and
het KPC as compared to KPC cohort at 10, 15 and 20 weeks. B. The percentage of tumorbearing animals was significantly higher in het KPC compared to KPC at 20-week. Most
of the KPCP animals succumbed before reaching 20-week time point. C. Representative
H and E stained picture of pancreatic tumors from 28-week KPC, 20-week het KPC and
15-week KPCP mice. KPC mice pancreatic tumors displayed well-differentiated
pancreatic tumor histology, whereas poorly differentiated/undifferentiated tumor histology
was observed for KPCP tumors. Whole slides containing pancreatic sections were
scanned at TSF. Here enlarged pictures at 40X magnification are shown.
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Figure 13: Knockout of Paf1 significantly decreased overall survival.
Survival analysis of KPC and KPCP mice using Kaplan Meir approach shows that genomic
depletion of Paf1 in KPCP mice significantly decreased median survival as compared to
KPC mice. (n=11 for KPC and KPCP). KPCP mice has significantly decreased median
survival (104 days) as compared to KPC mice (200 days). The median survival for
heterozygous Paf1 deletion in the background of Kras and Trp53 mutations was
intermediate between KPCP and KPC mice (134 days). Log-rank test was used to analyze
significance (P <0.0001).
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Figure 13

Log-rank, P <0.0001
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Figure 14: Higher expression mesenchymal marker Vimentin in KPCP tumors and
tumor-derived cell line.
A. Cell lines derived from 15-week KPCP and KPC tumors were analyzed for expression
of mesenchymal markers Vimentin, Snail and epithelial marker ZO-1 by immunoblotting.
Actin was used as a loading control. B. Scatter dot plot demonstrates significant increase
of Vimentin composite score in KPCP tumors as compared to KPC tumors (n=5 for KPC
and KPCP mice); Bottom panel: Representative histologic pictures showing increased
Vimentin staining in KPCP tumors as compared to KPC tumors. *P<0.05; by Wilcoxon
Signed Rank Test.

179

Figure 14
A

B

180

Figure 15: Representative models depicting modes of acinar regeneration and
progression to pancreatic ductal adenocarcinoma.
A. Damage to the acinar compartment can manifest through acinar cells dying or
transdifferentiating to ductal cells through acinar-to-ductal metaplasia. Damaged acinar
cells undergo regeneration either through proliferation of pre-existing acinar cells or by redifferentiation of ductal cells back to functional acinar state. Chronic inflammation and
oncogenic insults cause persistent ADM and generation of PanINs that ultimately progress
to PDAC. B. Loss of Paf1 results in persistent inflammation and ADM-like histology. This
dedifferentiated state is a vulnerability that allows for a greater impact following Kras and
p53 mutations and results in faster PDAC progression. .
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Figure 16: Hypothetical model for elucidating the tumor suppressive and tumor
promoting roles of Paf1. A. Inducible Paf1 depletion from adult pancreas at earlier
stages of PDAC pathogenesis may cause enhanced PDAC progression, suggesting
tumor-suppressive role for Paf1. B. Inducible overexpression of Paf1 at later stages of
PDAC pathogenesis in mice that exhibit PanINs may result in more aggressive tumors,
indicating tumor-promoting role of Paf1. C. Similarly, decreased PDAC progression upon
inducible deletion of Paf1 at later stages of disease pathogenesis would bolster the tumor
maintenance role of Paf1.
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Table 1: Sequence of genotyping primers for Paf1 5’ and 3’ LoxP arm

5’ Genotyping Primers
Forward

GCCTCAACCTTCCTCGGACTGGC

Reverse

GGAGAGGAACTCTGAATGCAAG
3’ Genotyping Primers

Forward

CTTGCATTCAGAGTTCCTCTCC

Reverse

GGACCCACCTCACCTCTTAG
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CHAPTER 6

Summary, Conclusions, and Future
Directions
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1. Summary and Conclusions
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease that has the lowest 5-year
survival rate among cancers at only 9% [1]. This poor survival is attributed to the extensive
metastatic spread of tumor cells beyond the pancreas at diagnosis and the inability of
current therapeutic modalities to treat this aggressive disease effectively. The current
standard chemotherapy for PDAC is effective in about 10-30% of cases [2]. Drug
resistance and aggressiveness of PDAC has been attributed to cancer cells with ‘stemlike’ properties known as cancer stem cells (CSCs) [3, 4]. Further, even though the genetic
driver mutations for PDAC have been identified, a clear understanding of initial events of
PDAC initiation is still lacking [5, 6]. Origin of PDAC from acinar versus ductal cells
continues to be a topic of debate [7]. Even though acinar cells are considered to be more
plastic than ducts, are all acinar cells equally receptive to external stimuli for
transdifferentiation, or are there subpopulations of acini that are more plastic? Are there
reserve progenitors within the pancreas or facultative progenitors that are created when
the need arises? [6, 8, 9]. At present, there is an immediate need to identify those factors
that promote the trans-differentiation process and contribute to tumor induction, as well as
those required for CSC maintenance that contributes to tumor maintenance and
aggressiveness.
In this dissertation research, we attempted to address these knowledge gaps by
studying a novel CSC maintenance protein, PAF1, and delineating its role in pancreas
homeostasis and cancer pathogenesis. To achieve this, we formulated three major goals.
First, we investigated the mechanistic role of PAF1 in supporting pancreatic CSCs and
sought to identify a means for therapeutically targeting CSCs. Second, we explored the
impact of Paf1 depletion on the pancreas homeostasis in vivo through a CRISPR/Cas9based conditional knockout mouse model. Finally, to understand the contribution of Paf1
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to PDAC progression, we generated the KPCP mouse model, which had homozygous
pancreas-specific Paf1 deletion in the background of endogenous expression of mutant
Kras and Trp53.
Concisely, we found a PAF1 complex independent role for PAF1 in the maintenance of
pancreatic CSCs. Importantly, we found that pancreatic CSCs could be selectively
targeted with a DDX3 inhibitor, RK-33. Using a novel CRISPR-based conditional PAF1
knockout mouse model, we identified that Paf1 plays a role in lineage differentiation and
acinar regeneration. Further, through studies with the KPCP (KrasG12D; Trp53R172H/+;
Paf1fl/fl; Pdx1-Cre) model, we found that loss of Paf1 results in faster PDAC progression.
The summary of all three research goals is described below:
A. PAF1 maintains pancreatic CSCs independently of the canonical PAF1C via
PHF5A and DDX3
RNA polymerase II-associated factor 1 (PAF1) was identified in a differential screen for
markers of differentiation and found to be more than 30-fold overexpressed in the more
aggressive, poorly differentiated tumors compared to well-differentiated tumors [10]. PAF1
is a core component of human RNA polymerase II-associated factor 1 complex (PAF1C),
which recruits RNA polymerase II for transcriptional elongation. The canonical PAF1C
consists of 5 members: PAF1, LEO1, CTR9, CDC73, and SKI8. Our previous work
demonstrated that PAF1 is a novel CSC marker that has been attributed to drug resistance
and metastasis in PDAC [11, 12]. The first indication of a function for PAF1 in stem cells
was from studies in mouse embryonic stem cells (ESCs), showing PAF1 interacts with
pluripotency master regulator Oct3/4, thereby facilitating self-renewal potential [13].
Moreover, PAF1 also regulates RNA polymerase II pause release from stem cell loci [1416]. Because maintenance mechanisms for CSCs remain obscure, it is important to
understand the factors that support these cells, especially in PDAC.
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First, we investigated the impact of the loss of PAF1 on pancreatic tumorigenesis.
We found that PAF1 downregulation impaired the formation of pancreatic tumors in
orthotopic and subcutaneous mouse models using multiple PDAC cell lines. Moreover,
the metastatic burdens to the liver, stomach, and intestine were reduced upon PAF1
depletion in PDAC xenograft tumors. Further, we found PAF1 depletion significantly
decreased various CSC populations (CSCs with high expression of CD44, cells with high
ALDH activity, and SP cells) and expression of CSC markers, suggesting that the
decreased tumorigenesis on PAF1 depletion is due to the role of PAF1 in CSC
maintenance. Having established that PAF1 plays a role in CSCs, we next wanted to
understand the importance of PAF1 in purified CSC populations. PAF1 was
overexpressed in isolated CSCs and essential for regulating the phenotypic features of
CSCs such as in vitro tumor sphere formation and colony formation. Further, PAF1
depletion in CSCs led to downregulation of stemness genes (Gata3, Elk1, Stat3, Stat5b,
Stat6, Jun-B, Cebpb, Cebpa, Ctnnb1, Crebbp, and Foxa2) and tumor-promoting pathways
(JAK/STAT signaling, IL-6 signaling, ERK/MAPK signaling, and CXCR4 signaling).
Interestingly, the other PAF1C subunits, LEO1, CTR9, and CDC73, appear dispensable
for the maintenance of stem cell state, as their downregulation affected neither the
expression of CSC markers nor the formation of tumor spheres. Also, loss of PAF1 in
CSCs did not alter the expression of other PAF1C subunits, indicating a possible complex
independent role for PAF1. We hypothesized that the canonical PAF1C-independent role
of PAF1 is mediated through its interaction with other proteins. Through IP-mass
spectrometry, we identified PHD finger protein 5a (PHF5A) and DEAD-box RNA helicase
3 (DDX3) as unique interacting partners for PAF1 in CSCs. We used a global approach to
identify the genes that are jointly regulated by PAF1 and PHF5A by performing chromatin
immunoprecipitation sequencing (ChIP-Seq) with PAF1 and PHF5A-pulldown in CSCs.
Promoters of several stemness regulators, including Nanog, SOX9, ABCB5, ERBB2, LIF,
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POU5F1, and others, were occupied by PAF1 and PHF5A in SW1990 SP cells. Nanog
was amongst the top genes whose promoters were jointly occupied by PAF1 and PHF5A
in SW1990 SP cells. The knockdown of PAF1 and PHF5A led to a significant
downregulation of Nanog, as observed by immunoblot and qRT-PCR analysis. Consistent
with the roles of Nanog and PAF1 in CSC maintenance, we observed co-overexpression
of PAF1 and Nanog in human PDAC tissues compared to the normal pancreas and poorer
survival in patients with higher expression of Nanog.
Since we found the role of the PAF/PHF5A/DDX3 sub-complex in pancreatic CSC
maintenance, we next sought to determine a means of disrupting this sub-complex to
target CSCs. To this end, we investigated the effect of RK-33, a specific small-molecule
inhibitor of DDX3 helicase activity. Treatment of CSCs with RK-33 led to a significant
downregulation of CSC markers (β-CATENIN, CD44v6, SOX9, and NANOG), and
inhibition of tumor sphere formation and colony formation. Further, the effect of RK-33 on
the expression of CSC markers in non-CSCs was not as profound as that seen with CSCs.
Additionally, treatment with RK-33 resulted in apoptosis of CSCs, while minimal cell death
was seen in normal human fibroblasts, supporting the clinical applicability of RK-33.
Overall, these data indicate that PAF1 functions as the master regulator for stem cell
maintenance by regulating the transcription of several stem cell-related genes via a
PAF1C-independent mechanism.
B. CRISPR/Cas9-mediated conditional knockout of Paf1 revealed that Paf1 plays a
role in acinar maintenance and lineage differentiation
Prior studies have shown that PAF1 plays a role in mediating ADM, a regenerative process
that converts acinar cells to ductal cells and generates PanINs (pancreatic intraepithelial
neoplasias) that ultimately lead to PDAC [17, 18]. Further, ectopic overexpression of PAF1
in PDAC cells results in enhanced tumorigenesis and metastasis in xenograft studies [11].
These studies suggest that PAF1 plays a role in promoting pancreatic tumorigenesis.
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Moreover, our in vitro studies with human PDAC cells delineated the essential role that
PAF1 plays in supporting pancreatic CSCs. Given that emerging literature suggests the
plasticity of pancreatic epithelial cells and allude to the origin of PDAC from a plastic ‘stemlike’ compartment that is expanded under pancreatic inflammation or injury [19-22], we
intended to investigate the role of PAF1 in the pathogenesis of PDAC using mouse
models. Since the whole-body knockout of Paf1 is embryonic lethal, we used a CRISPRbased conditional knockout mouse model for the pancreas-specific deletion of Paf1.
For generating the Paf1 conditional knockout mouse model, we used a novel
genome-editing tool called Isi-CRISPR (ivTRT-ssDNA-insertion-CRISPR) to insert loxP
sites flanking exon 4. Paf1 homozygous floxed (Paf1fl/fl) mice were crossed with Pdx-1Cre mice to generate mice with pancreas-specific Paf1 deletion (Paf1-/-). Homozygous
Paf1 deleted mouse pancreata were harvested at early (1-month, 2-month, 3-month, and
4-month age) and late (7-month, 9-month, 12-month age) time points along with agematched control tissues. The deletion of Paf1 from the mouse pancreas caused a
significant decrease in pancreas weight in young mice (up to 5-month age), without
affecting the body weight. Histologically, Paf1 loss caused extensive loss of acinar
parenchyma with associated inflammation and appearance of ‘naked ducts’ embedded in
fat, as noted by two pathologists. Immunohistochemical analyses showed a decrease in
Paf1 expression. However, the ‘naked-duct like’ phenotype was restored in older mice (7month, 9-month, and 12-month age). Similarly, the pancreas weight of Paf1-deleted and
floxed mice at later time points did not differ significantly. RNA-seq analyses of the
pancreas from homozygous Paf1-deleted and floxed mice revealed that top
downregulated genes belonged to pathways prevalent in system development, pancreas
cell fate determination, and survival. Some of these transcripts downregulated following
Paf1 loss include Notch2 (cell fate and differentiation), Tbx19 (regulation of developmental
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processes), Fgf7 (proliferation of pancreatic epithelial cells), Foxo6 (cell fate decisions),
Atf-3 (glucose and insulin homeostasis), Klf7 (cellular differentiation and insulin secretion).
Collectively, these results indicate that Paf1 plays a role in acinar lineage differentiation
and maintenance.
C. Genomic depletion of Paf1 in the background of Kras and p53 mutations
accelerates PDAC progression
Our next goal was to study the role of Paf1 in PDAC progression. We used the
autochthonous PDAC progression model (KPC model) that consists of triple transgenic
animals (KrasG12D; Trp53R172H/+; Pdx-1-Cre). The homozygous Paf1 floxed (Paf1fl/fl) mice
were crossed with KPC mice to generate Paf1 knockout in the background of the targeted
expression of a KrasG12D allele and Trp53R172H/+ (designated as the KPCP mice). To study
the impact of Paf1 deletion on disease progression, we evaluated KPCP (KrasG12D;
Trp53R172H/+; Pdx-1-Cre; Paf1fl/fl), KPC, and age-matched het KPC (KrasG12D; Trp53R172H/+;
Pdx-1-Cre; Paf1fl/+) mice at several time points, which included 3, 5, 10, 15, and 20 weeks.
To our surprise, the loss of Paf1 in the context of KPC background significantly
accelerated disease progression. Low-grade PanIN lesions were observed in just three
weeks. High-grade PanINs were observed as early as five weeks and were significantly
more frequent at 10 and 15 weeks in KPCP mice than KPC controls. PDAC progression
in KPCP mice was very rapid as compared to KPC mice, which usually develops PanIN
lesions by 10 weeks and full-blown tumors by 20-25 weeks. Further, KPCP mice showed
greater tumor incidence than KPC mice at 5, 10, and 15 weeks. Histopathologic analysis
of KPCP tumors revealed poorly differentiated/undifferentiated morphology; however, a
vast majority of KPC animals showed well to moderately differentiated tumors. The median
survival of KPC control littermates was around 200 days (28.6 weeks), whereas KPCP
mice have a dramatically shortened median survival of 104 days (14.8 weeks). Cell lines
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derived from KPCP mice showed a significantly higher expression of mesenchymal
markers (Vimentin, Snail, and Slug) compared to KPC cell lines. Altogether, our studies
demonstrated that loss of Paf1 leads to more aggressive PDAC progression.
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2. Future Directions
A. PAF1 maintains pancreatic CSCs independently of the canonical PAF1C via
PHF5A and DDX3
(i) Does DDX3 inhibition affect CSC maintenance in PDAC autochthonous mouse
models?
Our in vitro studies showed that the treatment of CSCs with DDX3 inhibitor, RK-33
significantly downregulated CSC markers, whereas the effect of RK-33 on non-CSCs was
not as profound. Further, RK-33 demonstrated minimal toxicity to normal human fibroblast
cell lines. RK-33 has previously been tested in an immune-competent Twist1/KrasG12D
autochthonous lung tumor model and an orthotopic human xenograft model for lung
cancer. In this study, the authors demonstrated that RK-33 induces radiosensitization in
preclinical mouse models of lung cancer [23]. These findings suggest that evaluating RK33 in PDAC autochthonous mouse models will be informative and could potentially pave
the way for new therapeutic avenues for targeting pancreatic CSCs. In the future, we could
treat KC (KrasG12D; Pdx-1-Cre) and KPC (KrasG12D; Trp53R172H/+; Pdx1-Cre) PDAC mouse
models with RK-33 and evaluate tumor growth, disease progression, and CSC
maintenance.
(ii) Does PAF1 depletion influence CSC-mediated tumor recurrence in vivo?
In the first research goal of this dissertation, we established the mechanistic role of PAF1
in pancreatic CSC maintenance. Given that tumor recurrence is believed to be driven by
the sub-populations of CSCs that are left unharmed by chemotherapeutic regimens, it will
be interesting to investigate the impact of the loss of PAF1 on tumor recurrence. Such
experiments can be challenging in vivo as it would entail the removal of pancreatic tumors
from mice and then subjecting surviving mice to chemotherapy. Due to the location of the
pancreas deep within the peritoneum, the survival of animals undergoing this surgery
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becomes a technical difficulty in such experiments. Another approach to investigate tumor
recurrence in vivo entails developing a dormant tumor by subcutaneous implantation in
one flank of nude mice and study of triggers that re-awaken the dormant tumor cells
following implantation of tumor cells in the other flank [24]. While this approach overcomes
the survival challenge, there might be other challenges in achieving and breaking tumor
dormancy. Nonetheless, it will be extremely informative to use either approach to study
the role of PAF1 in mediating tumor recurrence.
(iii) Does PAF1 play a role in regulating metabostemness?
Metabolism of cancer and CSCs is an emerging area of cancer research. Recent evidence
alludes to metabolic infrastructural changes being a key factor in dictating cellular
differentiation states and not merely a passive by-product of oncogene-driven
transformation. Metabolic reprogramming appears to be fundamental in deciding cell fate,
given that transformation of cellular metabolism precedes changes in stemness [25].
Indeed, tight regulation of the metabolic master switches contributes to the metabolic
changes that occur in the transition between a differentiated cell and a stem cell [26, 27].
The acquisition of or loss of stemness in pre-malignant and cancer tissues is not
exclusively regulated by genetic and epigenetic controllers, but also by the cellular
metabotype that functions as a molecular constraint controlling the kinetics of stemness
reprogramming during cancer genesis and progression. Here, certain metabolic shifts
might occur very early in the course of malignant transformation of a non-CSC to a CSC
state that might render a differentiated cell more susceptible to transcriptional and
epigenetic rewriting necessary for the acquisition of stemness. ‘Metabostemness’ refers
to the metabolic parameters causally controlling or functionally substituting the epigenetic
orchestration of the genetic program that directs normal and non-CSC tumor cells towards
a less-differentiated CSC cellular state [28, 29]. It is a new phenotypic cancer hallmark
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that refers to the metabolic parameters at the cell-intrinsic, tissue-microenvironmental, and
systemic levels that enable the functional properties of CSCs [30]. It is interesting that we
found oxidative phosphorylation and general metabolic pathways as being the top
differentially upregulated pathways in high PAF1 PDAC tumors from TCGA compared with
those tumors that showed low PAF1 expression (Figure 1). Given that PAF1 plays
important roles in regulating self-renewal and differentiation of stem cells, the implications
of PAF1 being a central player in metabostemness in PDAC are intriguing and warrant
further investigation.
(iv) What is the clinical relevance of DDX3?
We observed DDX3 to be overexpressed in isolated pancreatic CSCs and HPNE
oncogene-transformed progression model. However, a comprehensive analysis of DDX3
expression in PDAC tumors based on histopathological and clinical parameters may be
performed in future. This will be especially helpful in categorizing patients for RK-33
treatment. Further, it will be interesting to correlate DDX3 expression with other stemness
marker signatures through bioinformatic analyses using available databases.
B. CRISPR/Cas9-mediated conditional knockout of Paf1 revealed that Paf1 plays a
role in acinar regeneration
(i) Does Paf1 affect the overall metabolism of cells?
Differential analyses of genes affected by pancreas-specific Paf1 depletion on a global
scale through RNA-Seq revealed enrichment of metabolic pathways besides system
development. This observation is in line with our analysis of pathways enriched in PAF1high
versus PAF1low tumors from TCGA. Given that both system development and metabolic
pathways were significantly enriched, we can ask whether the phenotype seen with acinar
cells alters the metabolic pathways of pancreatic cells or does alteration of metabolism
lead to acinar cell death and eventual regeneration. To address this question, we could
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use an inducible model for Paf1, such that the depletion is mediated by tamoxifeninducible Ptf1a-Cre. The use of an inducible system would allow us to delete Paf1 in adult
mice as opposed to embryonic activation of the promoter in Pdx1-Cre. In that scenario,
we could treat the adult mice with inhibitors of endoplasmic reticulum (ER) stress to
prevent acinar cell death, and concomitantly investigate the effect of Paf1 deletion on the
metabolism of pancreatic epithelial cells.
C. Genomic depletion of Paf1 in the background of Kras and p53 mutations
accelerates PDAC progression
(i) What is the temporal pattern of tumor-suppressive versus tumor-promoting
functions of Paf1?
We observed that loss of Paf1 led to acinar regeneration, whereas depletion of Paf1 in the
context of Kras and p53 mutations accelerated PDAC progression. These findings can be
reconciled if we consider that Paf1 plays a stage-dependent role during PDAC
progression, wherein it is tumor suppressive in pre-neoplastic PanINs and tumorpromoting in fully developed later PDAC stages. This notion is partly corroborated by our
findings of higher incidence of PanINs and faster PDAC progression due to the depletion
of Paf1 from pancreatic progenitors since birth using Pdx1-Cre. However, what causes
Paf1 to switch from a tumor-suppressive to a tumor-promoting role? This can be
addressed by developing a PDAC progression model with inducible Paf1 overexpression
such as under the control of Ptf1a-Cre (KrasG12D/+; Trp53R172H/+; Ptf1a-Cre; Paf1fl/fl). Such
a system would allow overexpression of Paf1 in adult mice concomitantly with endogenous
mutant Kras and p53, thus enabling determination of its tumor suppressive roles in adult
mice. However, turning on Paf1 overexpression in advanced PDAC stages such as 15-20
weeks KPC will allow us to dissect the tumor-promoting functions of Paf1.
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(ii) Does DDX3 inhibition alter PDAC progression in the KPCP mouse model?
Since KPCP mouse model represents faster PDAC progression, it can possibly be utilized
for therapeutic studies. In our first research aim, we found that treatment with DDX3
inhibitor, RK-33 was effective in eliminating pancreatic CSCs. As mentioned previously,
RK-33 has been tested in autochthonous lung cancer models in combination with
radiotherapy and chemotherapy [23]. Efficacy for RK-33 to control PDAC progression and
metastasis can be tested in KPCP model. Further, this model can be used for determining
the impact of RK-33 treatment on various CSC populations. These clinical studies on
mouse models could pave the way for targeting PDAC.
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Figure Legends
Figure 1: Bioinformatic analyses of TCGA PDAC dataset shows enrichment of
metabolic pathways in PAF1high tumors.
The normalized PDAC gene expression data (FPKM-UQ) was obtained from TCGA
(portal.gdc.cancer.gov). We split the samples (n = 177) into two cohorts, namely “high
PAF1” and “low PAF1” based on their PAF1 median gene expression. Subsequently, we
performed functional enrichment analysis using Gene Set Enrichment Analysis (GSEA)
with

Reactome,

HALLMARK,

and

GO-BP

gene

sets

databases

to

identify

annotations/pathways associated with PAF1 expression.

A. Diagram depicting Reactome and Gene Ontology biological processes enriched
in high PAF1 PDAC tumors. The circumference of the circle represents the
enrichment value. Higher the circumference of the circle, greater is the enrichment
value. B. GSEA enrichment plot representing significant enrichment of oxidative
phosphorylation hallmark in high PAF1 tumors.
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